aspirin and Venous Thrombosis studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Venous Thrombosis: The formation or presence of a blood clot (THROMBUS) within a vein.

Research Excerpts

Excerpt	Relevance	Reference
" No significant differences in deep venous thrombosis, pulmonary embolism, and bleeding complications rates were found between aspirin and LMWH."	9.41	The role of aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis after total knee arthroplasty: a meta-analysis of randomized controlled trials. ( Gao, S; Liu, W; Meng, J; Tang, H; Wu, Y; Xiao, Y, 2023)
" The COMMANDER HF randomized clinical trial evaluated the effects of adding low-dose rivaroxaban to antiplatelet therapy in patients with recent worsening of chronic HF with reduced ejection fraction, coronary artery disease (CAD), and sinus rhythm."	9.30	Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. ( Anker, SD; Byra, WM; Cleland, JGF; Deng, H; Fu, M; Greenberg, B; La Police, DA; Lam, CSP; Mehra, MR; Neaton, JD; Nessel, CC; Spiro, TE; van Veldhuisen, DJ; Vanden Boom, CM; Zannad, F, 2019)
"Aspirin at 325 mg twice daily is now included as a nationally approved venous thromboembolism (VTE) prophylaxis protocol for low-risk total knee arthroplasty (TKA) patients."	9.24	Efficacy in Deep Vein Thrombosis Prevention With Extended Mechanical Compression Device Therapy and Prophylactic Aspirin Following Total Knee Arthroplasty: A Randomized Control Trial. ( Gregg, JL; Hussain, LR; Scheuerman, CM; Snyder, MA; Sympson, AN, 2017)
"This study aimed to compare the efficacy and safety of aspirin, rivaroxaban and low-molecular-weight heparin (LMWH) for post total knee arthroplasty (TKA) deep vein thrombosis (DVT) prophylaxis."	9.19	Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty. ( Sun, K; Tian, S; Wang, Y; Zou, Y, 2014)
"Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE)."	9.16	Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. ( Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB, 2012)
"Aspirin reduced the risk of recurrence when given to patients with unprovoked venous thromboembolism who had discontinued anticoagulant treatment, with no apparent increase in the risk of major bleeding."	9.16	Aspirin for preventing the recurrence of venous thromboembolism. ( Ageno, W; Agnelli, G; Becattini, C; Bianchi, M; Bucherini, E; Eichinger, S; Grandone, E; Moia, M; Prandoni, P; Schenone, A; Silingardi, M; Vandelli, MR, 2012)
"To comprehensively evaluate the clinical effects of low molecular weight heparin (LMWH) and aspirin for deep vein thrombosis (DVT) patients after orthopaedic surgery."	9.12	Low molecular weight heparin and aspirin for prevention of deep vein thrombosisafter orthopaedic surgery: a systematic review and meta-analysis. ( Chen, B; Hu, N, 2021)
"Short-term aspirin therapy can lower the risk for venous thromboembolism (VTE) in high-risk patients, but whether the long-term use of low-dose aspirin reduces risk in healthy adults is uncertain."	9.12	Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. ( Buring, JE; Glynn, RJ; Goldhaber, SZ; Ridker, PM, 2007)
"To study the efficacy of daily low-dose aspirin (81 mg orally) in decreasing the incidence of venous thromboembolic events (VTEs) in patients with multiple myeloma receiving pegylated doxorubicin, vincristine, and decreased-frequency dexamethasone, plus thalidomide (DVd-T)."	9.11	The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. ( Andresen, S; Baz, R; Faiman, B; Hussein, MA; Jawde, RA; Karam, MA; Kottke-Marchant, K; Li, L; McGowan, B; Srkalovic, G; Yiannaki, E; Zeldis, J, 2005)
"A prospective, randomized controlled trial was used to compare the efficacy of the arteriovenous (AV) impulse system and aspirin in reducing venous thrombosis after fracture to the femoral neck."	9.09	Deep vein thrombosis prophylaxis in hip fractures: a comparison of the arteriovenous impulse system and aspirin. ( Dallo Vedova, PA; Griffen, DR; Kennedy, JG; Kumar, S; Rogers, BW; Sheehan, LJ; Soffe, KE; Sullivan, RJ, 2000)
"This randomised, double-blind, aspirin-controlled trial tested the safety and efficacy of treatment with high-dose tinzaparin (175 anti-Xa IU/kg daily; 487 patients), medium-dose tinzaparin (100 anti-Xa IU/kg daily; 508 patients), or aspirin (300 mg daily; 491 patients) started within 48 h of acute ischaemic stroke and given for up to 10 days."	9.09	Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. ( Bath, PM; Boysen, G; De Deyn, P; Friis, P; Leys, D; Lindenstrom, E; Marttila, R; O'Neill, D; Olsson, J; Orgogozo, J; Ringelstein, B; Turpie, AG; van der Sande, J, 2001)
"We presented a patient suffered from stroke related to thalidomide therapy."	8.84	[Brief report: stroke in multiple myeloma patient treated with thalidomide]. ( Hashimoto, Y; Hirano, T; Ito, Y; Mori, A; Uchino, M; Yonemura, K, 2007)
"While there is good evidence for a protective effect of aspirin against occlusive vascular events in individuals with arterial disease, its role in preventing venous thromboembolism (VTE) is unclear."	8.84	Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism. ( Chee, YL; Watson, HG, 2008)
"This review summarizes available evidence on effects of aspirin on incidence and outcomes of venous thromboembolism (VTE)."	8.83	Aspirin in the prevention and treatment of venous thromboembolism. ( Hovens, MM; Huisman, MV; Snoep, JD; Tamsma, JT, 2006)
"Although the effect of rectal indomethacin in post-endoscopic retrograde cholangiopancreatography pancreatitis is well established, the effect of aspirin on acute pancreatitis (AP) is not well studied."	8.31	Does use of long-term aspirin impact outcomes in patients with acute pancreatitis? ( Chaudhry, H; Dukovic, D; Kohli, I; Prajapati, D; Sharma, R; Singla, P; Sohal, A; Yang, J, 2023)
"To evaluate whether a daily full-dose aspirin regimen after anterior cruciate ligament (ACL) reconstruction reduces the risk of postoperative symptomatic deep-venous thrombosis (DVT)."	8.02	Aspirin for Deep-Venous Thrombosis Prophylaxis After Anterior Cruciate Ligament Reconstruction. ( Bernstein, EM; Briggs, AM; Ferris, WJ; Hurvitz, AP; McDonald, LS; McIntire, SC; Renninger, CH; Tompane, TM, 2021)
" However, aspirin (ASA) is routinely used for chemoprophylaxis of deep vein thrombosis (DVT) and is gaining popularity for use after treatment of ankle fractures."	7.96	Postoperative aspirin use and its effect on bone healing in the treatment of ankle fractures. ( Anderson, M; Hunter, AM; McGwin, G; Montgomery, TP; Moraes, L; Pitts, CC; Shah, A; Wilson, J, 2020)
"The purpose of this meta-analysis is to compare the efficacy and safety of aspirin and rivaroxaban in the prevention of venous thromboembolism (VTE) following either total knee arthroplasty or total hip arthroplasty."	7.96	Efficacy and safety of aspirin and rivaroxaban for venous thromboembolism prophylaxis after total hip or knee arthroplasty: A protocol for meta-analysis. ( Le, G; Luo, H; Tang, J; Xi, L; Yang, C; Zhang, M; Zhao, J, 2020)
" Aspirin has been considered a safe and cost-effective prophylaxis for venous thromboembolism (VTE), and there have been some reports about the incidence of PTE (0%-0."	7.96	Clinical efficacy of risk-stratified prophylaxis with low-dose aspirin for the management of symptomatic venous thromboembolism after total hip arthroplasty. ( Hirakawa, K; Mihara, M; Nakura, N; Ochiai, S; Saito, A; Takayanagi, S; Tamaki, Y, 2020)
"Aspirin is an effective prophylaxis for venous thromboembolism (VTE) after total knee arthroplasty (TKA)."	7.88	Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prophylaxis Following Total Knee Arthroplasty. ( Barsoum, WK; Brigati, DP; Faour, M; Higuera, CA; Klika, AK; Mont, MA; Piuzzi, NS, 2018)
"ESSENTIALS: We audited venous thromboembolism (VTE) in Achilles injuries after the use of prophylactic aspirin."	7.83	Venous thromboembolism rates in patients with lower limb immobilization after Achilles tendon injury are unchanged after the introduction of prophylactic aspirin: audit. ( Beasley, R; Braithwaite, I; Dunbar, L; Eathorne, A; Weatherall, M, 2016)
"Although venous thromboembolism is one of the leading causes of morbidity after knee arthroplasty, little data exist on the risk of deep venous thrombosis (DVT) after unicompartmental knee arthroplasty (UKA)."	6.84	Deep Venous Thrombosis Prophylaxis After Unicompartmental Knee Arthroplasty: A Prospective Study on the Safety of Aspirin. ( Boettner, F; Mayman, DJ; Pearle, AD; Schmidt-Braekling, T; Waldstein, W; Westrich, GH, 2017)
"However, more recently, the rate of deep vein thrombosis (DVT) has been reported to be approximately 10%."	6.80	Prevention of Venous Thromboembolism after Arthroscopic Knee Surgery in a Low-Risk Population with the Use of Aspirin. A Randomized Trial. ( Alaia, MJ; Garofolo, G; Jazrawi, LM; Kaye, ID; Martinez, A; Patel, DN; Strauss, EJ, 2015)
"Symptomatic or asymptomatic deep vein thrombosis (DVT) is a common complication following coronary artery bypass graft (CABG), in which less than 1% of these patients suffer from clinically evident pulmonary embolism (PE)."	6.78	Comparison of aspirin plus heparin with heparin alone on asymptomatic perioperative deep vein thrombosis in candidates for elective off-pump coronary artery bypass graft: a randomized clinical trial. ( Ali-Hasan-Al-Saegh, S; Forouzannia, SK; Mirhosseini, SJ; Mostafavi Pour Manshadi, SM; Naderi, N; Sanatkar, M, 2013)
"Is it better to continue treatment of deep venous thrombosis or pulmonary embolism with LMWH or switch to an oral anticoagulant? What is the optimal duration of treatment? To answer these questions, we conducted a review of the literature using the standard Prescrire methodology."	6.49	Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months. ( , 2013)
"In this pilot study, there were no significant differences in any outcome assessed; however, recurrent thromboembolic events and minor bleeding events occurred numerically less frequently in the rivaroxaban plus aspirin group."	5.69	Rivaroxaban plus aspirin versus acenocoumarol to manage recurrent venous thromboembolic events despite systemic anticoagulation with rivaroxaban. ( Erika, MH; Jaime, GC; Maximiliano, CL, 2023)
"In patients with extremity fractures that had been treated operatively or with any pelvic or acetabular fracture, thromboprophylaxis with aspirin was noninferior to low-molecular-weight heparin in preventing death and was associated with low incidences of deep-vein thrombosis and pulmonary embolism and low 90-day mortality."	5.69	Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture. ( Bosse, MJ; Carlini, AR; Castillo, RC; Degani, Y; Firoozabadi, R; Frey, KP; Goldhaber, SZ; Haut, ER; Marvel, D; O'Hara, NN; O'Toole, RV; Obremskey, W; Scharfstein, DO; Slobogean, GP; Stein, DM; Sudini, K; Taylor, TJ, 2023)
"Warfarin treatment within 12 months achieved significantly higher rates of complete recanalization than aspirin or clopidogrel in patients with PVT (54."	5.48	Portal Vein Thrombosis in Patients With Cirrhosis Undergoing Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors, Warfarin Efficacy, and Clinical Outcomes. ( Li, YH; Wu, HM; Xu, Y; Yang, J; Yang, LH; Yue-Meng, W, 2018)
"Aspirin was associated with a significant protective effect in multivariate analysis, with an odds ratio of 0."	5.43	Aspirin as added prophylaxis for deep vein thrombosis in trauma: A retrospective case-control study. ( Bansal, V; Brill, JB; Calvo, RY; Lewis, PR; Shackford, SR; Sise, MJ; Wallace, JD, 2016)
"The rate of surgical site infection was similar between the aspirin group and the warfarin group (1."	5.43	Aspirin Can Be Used as Prophylaxis for Prevention of Venous Thromboembolism After Revision Hip and Knee Arthroplasty. ( Chen, AF; Deirmengian, GK; Heller, S; Maltenfort, M; Parvizi, J; Smith, EB, 2016)
" No significant differences in deep venous thrombosis, pulmonary embolism, and bleeding complications rates were found between aspirin and LMWH."	5.41	The role of aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis after total knee arthroplasty: a meta-analysis of randomized controlled trials. ( Gao, S; Liu, W; Meng, J; Tang, H; Wu, Y; Xiao, Y, 2023)
"(2) Aspirin has been tested in several placebo-controlled trials and has a positive risk-benefit balance, preventing about 5 deaths per 1000 patients with ischaemic stroke."	5.33	Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin. ( , 2005)
" The COMMANDER HF randomized clinical trial evaluated the effects of adding low-dose rivaroxaban to antiplatelet therapy in patients with recent worsening of chronic HF with reduced ejection fraction, coronary artery disease (CAD), and sinus rhythm."	5.30	Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. ( Anker, SD; Byra, WM; Cleland, JGF; Deng, H; Fu, M; Greenberg, B; La Police, DA; Lam, CSP; Mehra, MR; Neaton, JD; Nessel, CC; Spiro, TE; van Veldhuisen, DJ; Vanden Boom, CM; Zannad, F, 2019)
"Venous thrombosis was reduced 56% by oral soluble acetylsalicylic acid and 27% by oral aspirin."	5.30	Some effects of prophylactic aspirins and heparins on concurrent arterial and venous thrombosis in the same animal. ( Iomhair, MM; Lavelle, SM, 1998)
"Aspirin at 325 mg twice daily is now included as a nationally approved venous thromboembolism (VTE) prophylaxis protocol for low-risk total knee arthroplasty (TKA) patients."	5.24	Efficacy in Deep Vein Thrombosis Prevention With Extended Mechanical Compression Device Therapy and Prophylactic Aspirin Following Total Knee Arthroplasty: A Randomized Control Trial. ( Gregg, JL; Hussain, LR; Scheuerman, CM; Snyder, MA; Sympson, AN, 2017)
"We conducted a prospective, single-center, active controlled study from July 2013 to January 2015, in Chinese patients with rapid ventricular arrhythmia who had received radiofrequency catheter ablation (RFCA) treatment to determine formation of lower extremity deep vein thrombosis (LDVT) post RFCA procedure, and evaluated the effect of rivaroxaban on LDVT."	5.22	Prevention and Treatment of Lower Limb Deep Vein Thrombosis after Radiofrequency Catheter Ablation: Results of a Prospective active controlled Study. ( Jiang, SB; Li, L; Liu, XZ; Ma, J; Zhang, BJ; Zhang, BK, 2016)
"This study aimed to compare the efficacy and safety of aspirin, rivaroxaban and low-molecular-weight heparin (LMWH) for post total knee arthroplasty (TKA) deep vein thrombosis (DVT) prophylaxis."	5.19	Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty. ( Sun, K; Tian, S; Wang, Y; Zou, Y, 2014)
"Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE)."	5.16	Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. ( Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB, 2012)
"Aspirin reduced the risk of recurrence when given to patients with unprovoked venous thromboembolism who had discontinued anticoagulant treatment, with no apparent increase in the risk of major bleeding."	5.16	Aspirin for preventing the recurrence of venous thromboembolism. ( Ageno, W; Agnelli, G; Becattini, C; Bianchi, M; Bucherini, E; Eichinger, S; Grandone, E; Moia, M; Prandoni, P; Schenone, A; Silingardi, M; Vandelli, MR, 2012)
"To comprehensively evaluate the clinical effects of low molecular weight heparin (LMWH) and aspirin for deep vein thrombosis (DVT) patients after orthopaedic surgery."	5.12	Low molecular weight heparin and aspirin for prevention of deep vein thrombosisafter orthopaedic surgery: a systematic review and meta-analysis. ( Chen, B; Hu, N, 2021)
"Deep vein thrombosis prevention efficacy using a new, miniature, mobile, battery-operated pneumatic system (continuous enhanced circulation therapy [CECT] system) combined with low-dose aspirin was compared to enoxaparin."	5.12	Deep vein thrombosis prevention in joint arthroplasties: continuous enhanced circulation therapy vs low molecular weight heparin. ( Gelfer, Y; Halperin, N; Oron, A; Peer, A; Robinson, D; Tavor, H, 2006)
"Short-term aspirin therapy can lower the risk for venous thromboembolism (VTE) in high-risk patients, but whether the long-term use of low-dose aspirin reduces risk in healthy adults is uncertain."	5.12	Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. ( Buring, JE; Glynn, RJ; Goldhaber, SZ; Ridker, PM, 2007)
"To study the efficacy of daily low-dose aspirin (81 mg orally) in decreasing the incidence of venous thromboembolic events (VTEs) in patients with multiple myeloma receiving pegylated doxorubicin, vincristine, and decreased-frequency dexamethasone, plus thalidomide (DVd-T)."	5.11	The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. ( Andresen, S; Baz, R; Faiman, B; Hussein, MA; Jawde, RA; Karam, MA; Kottke-Marchant, K; Li, L; McGowan, B; Srkalovic, G; Yiannaki, E; Zeldis, J, 2005)
"A prospective, randomized controlled trial was used to compare the efficacy of the arteriovenous (AV) impulse system and aspirin in reducing venous thrombosis after fracture to the femoral neck."	5.09	Deep vein thrombosis prophylaxis in hip fractures: a comparison of the arteriovenous impulse system and aspirin. ( Dallo Vedova, PA; Griffen, DR; Kennedy, JG; Kumar, S; Rogers, BW; Sheehan, LJ; Soffe, KE; Sullivan, RJ, 2000)
"This randomised, double-blind, aspirin-controlled trial tested the safety and efficacy of treatment with high-dose tinzaparin (175 anti-Xa IU/kg daily; 487 patients), medium-dose tinzaparin (100 anti-Xa IU/kg daily; 508 patients), or aspirin (300 mg daily; 491 patients) started within 48 h of acute ischaemic stroke and given for up to 10 days."	5.09	Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. ( Bath, PM; Boysen, G; De Deyn, P; Friis, P; Leys, D; Lindenstrom, E; Marttila, R; O'Neill, D; Olsson, J; Orgogozo, J; Ringelstein, B; Turpie, AG; van der Sande, J, 2001)
"Focusing on the current state of the art, this article (a) describes recent advances in the understanding of the pathogenesis of venous thromboembolism (VTE), (b) discusses current approaches for the prevention, diagnosis and treatment of VTE, (c) outlines the role of aspirin for VTE prevention and treatment, and (d) highlights the unmet needs in VTE management and describes novel approaches to address them."	5.05	Recent advances in understanding, diagnosing and treating venous thrombosis. ( Chan, NC; Weitz, JI, 2020)
": Rivaroxaban, a direct oral anticoagulant, is widely used for the treatment of venous thromboembolism (VTE) in adult patients."	5.01	Rivaroxaban and the EINSTEIN clinical trial programme. ( Bauersachs, R; Cohen, AT, 2019)
"Aspirin, both alone and in multimodal approaches to thromboprophylaxis, confers a low rate of VTE, with a low risk of major bleeding complications."	4.93	Aspirin as Thromboprophylaxis in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis. ( An, VV; Bruce, WJ; Levy, YD; Phan, K, 2016)
" first venous thrombosis) should be treated with warfarin to an INR 2."	4.85	Management of antiphospholipid syndrome. ( Khamashta, MA; Tuthill, JI, 2009)
"Lenalidomide, an analog of thalidomide, is an effective new treatment for multiple myeloma."	4.84	Risk of thrombosis with lenalidomide and its prevention with aspirin. ( Hirsh, J, 2007)
" The relationship between low-dose aspirin and bleeding was explored by incidence rates and rates per 100 person-years."	4.84	Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. ( Bergsland, E; Gerber, HP; Holden, SN; Holmgren, E; Hurwitz, H; Kabbinavar, F; Miller, K; Ngai, J; Scappaticci, FA; Skillings, JR; Wang, J, 2007)
"We presented a patient suffered from stroke related to thalidomide therapy."	4.84	[Brief report: stroke in multiple myeloma patient treated with thalidomide]. ( Hashimoto, Y; Hirano, T; Ito, Y; Mori, A; Uchino, M; Yonemura, K, 2007)
"While there is good evidence for a protective effect of aspirin against occlusive vascular events in individuals with arterial disease, its role in preventing venous thromboembolism (VTE) is unclear."	4.84	Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism. ( Chee, YL; Watson, HG, 2008)
"This review summarizes available evidence on effects of aspirin on incidence and outcomes of venous thromboembolism (VTE)."	4.83	Aspirin in the prevention and treatment of venous thromboembolism. ( Hovens, MM; Huisman, MV; Snoep, JD; Tamsma, JT, 2006)
"Based on the established fact that anticoagulation with warfarin is superior to antiplatelet agents in the prevention of thromboembolic events in atrial fibrillation (AF), we propose that, in contrast to atherothrombotic disorders, the risk of developing a stroke or thromboembolic event in AF is more likely to be affected by the coagulation pathway than by platelet activity."	4.82	Atrial fibrillation: should we target platelets or the coagulation pathway? ( Lip, GY; Tan, KT, 2003)
"Anticoagulant therapy is indicated during pregnancy for the prevention and treatment of VTE; for the prevention and treatment of systemic embolism in patients with mechanical heart valves; and, often in combination with aspirin, for the prevention of pregnancy loss in women with APLAs or thrombophilia and previous pregnancy losses."	4.81	Use of antithrombotic agents during pregnancy. ( Ginsberg, JS; Greer, I; Hirsh, J, 2001)
" The purpose of this study was to define the efficacy and safety of the agents that are currently used for prophylaxis against deep venous thrombosis -- namely, low-molecular-weight heparin, warfarin, aspirin, low-dose heparin, and pneumatic compression."	4.80	A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. ( Brookenthal, KR; Fitzgerald, RH; Freedman, KB; Lonner, JH; Williams, S, 2000)
"Although the effect of rectal indomethacin in post-endoscopic retrograde cholangiopancreatography pancreatitis is well established, the effect of aspirin on acute pancreatitis (AP) is not well studied."	4.31	Does use of long-term aspirin impact outcomes in patients with acute pancreatitis? ( Chaudhry, H; Dukovic, D; Kohli, I; Prajapati, D; Sharma, R; Singla, P; Sohal, A; Yang, J, 2023)
" The incidence of VTE and hematoma formation was evaluated and compared between patients who received aspirin versus enoxaparin or heparin."	4.12	Does Aspirin Provide Adequate Chemoprophylaxis for Venous Thromboembolic Events in Operative Pelvic and Acetabular Fractures? ( Du, JY; Metcalf, KB; Ochenjele, G, 2022)
" Case presentation A 66-year-old Japanese male patient received regorafenib for metastatic colorectal carcinoma and apixaban for deep vein thrombosis."	4.02	Early stent thrombosis confirmed in a cancer patient receiving regorafenib, despite triple antithrombotic therapy: a case report. ( Matoba, S; Ookura, T; Shoji, K; Yanishi, K; Zen, K, 2021)
"To evaluate whether a daily full-dose aspirin regimen after anterior cruciate ligament (ACL) reconstruction reduces the risk of postoperative symptomatic deep-venous thrombosis (DVT)."	4.02	Aspirin for Deep-Venous Thrombosis Prophylaxis After Anterior Cruciate Ligament Reconstruction. ( Bernstein, EM; Briggs, AM; Ferris, WJ; Hurvitz, AP; McDonald, LS; McIntire, SC; Renninger, CH; Tompane, TM, 2021)
" However, aspirin (ASA) is routinely used for chemoprophylaxis of deep vein thrombosis (DVT) and is gaining popularity for use after treatment of ankle fractures."	3.96	Postoperative aspirin use and its effect on bone healing in the treatment of ankle fractures. ( Anderson, M; Hunter, AM; McGwin, G; Montgomery, TP; Moraes, L; Pitts, CC; Shah, A; Wilson, J, 2020)
"The purpose of this meta-analysis is to compare the efficacy and safety of aspirin and rivaroxaban in the prevention of venous thromboembolism (VTE) following either total knee arthroplasty or total hip arthroplasty."	3.96	Efficacy and safety of aspirin and rivaroxaban for venous thromboembolism prophylaxis after total hip or knee arthroplasty: A protocol for meta-analysis. ( Le, G; Luo, H; Tang, J; Xi, L; Yang, C; Zhang, M; Zhao, J, 2020)
" Aspirin has been considered a safe and cost-effective prophylaxis for venous thromboembolism (VTE), and there have been some reports about the incidence of PTE (0%-0."	3.96	Clinical efficacy of risk-stratified prophylaxis with low-dose aspirin for the management of symptomatic venous thromboembolism after total hip arthroplasty. ( Hirakawa, K; Mihara, M; Nakura, N; Ochiai, S; Saito, A; Takayanagi, S; Tamaki, Y, 2020)
"The results of this study clearly show that aspirin, as part of a multimodal thromboprophylactic regime, is an effective and safe regime in preventing venous thromboembolism with respect to risk of deep vein thrombosis or pulmonary embolism when compared to LMWH."	3.91	Clinical Effectiveness of Aspirin as Multimodal Thromboprophylaxis in Primary Total Hip and Knee Arthroplasty: A Review of 6078 Cases. ( Best, AJ; Chatterji, U; Ghosh, A; Rudge, SJ, 2019)
"The aims of this study were to compare the efficacy of two agents, aspirin and warfarin, for the prevention of venous thromboembolism (VTE) after simultaneous bilateral total knee arthroplasty (SBTKA), and to elucidate the risk of VTE conferred by this procedure compared with unilateral TKA (UTKA)."	3.88	Venous thromboembolic prophylaxis after simultaneous bilateral total knee arthroplasty: aspirin ( Fleischman, AN; Goel, R; Higuera, C; Huang, R; Parvizi, J; Rothman, RH; Sterbis, E; Tan, T, 2018)
"Aspirin and unfractionated heparin (UH) are accepted options for venous thromboembolism (VTE) prophylaxis after total joint arthroplasty (TJA)."	3.88	The Role of Aspirin and Unfractionated Heparin Combination Therapy Immediately After Total Hip and Knee Arthroplasty. ( Karadsheh, MS; Koueiter, DM; Mells, A; Siljander, MP; Sobh, AH, 2018)
"Aspirin is an effective prophylaxis for venous thromboembolism (VTE) after total knee arthroplasty (TKA)."	3.88	Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prophylaxis Following Total Knee Arthroplasty. ( Barsoum, WK; Brigati, DP; Faour, M; Higuera, CA; Klika, AK; Mont, MA; Piuzzi, NS, 2018)
"There was no evidence that fondaparinux, enoxaparin, or warfarin were superior to aspirin in the prevention of pulmonary embolism, deep vein thrombosis, or venous thromboembolism or that aspirin was safer than these alternatives."	3.85	Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty. ( Bini, SA; Cafri, G; Cheetham, CT; Chen, Y; Gould, MK; Khatod, M; Paxton, EW; Sluggett, J, 2017)
"ESSENTIALS: We audited venous thromboembolism (VTE) in Achilles injuries after the use of prophylactic aspirin."	3.83	Venous thromboembolism rates in patients with lower limb immobilization after Achilles tendon injury are unchanged after the introduction of prophylactic aspirin: audit. ( Beasley, R; Braithwaite, I; Dunbar, L; Eathorne, A; Weatherall, M, 2016)
"This study's purpose was to present our institution's experience with the use of a risk stratification protocol for venous thromboembolism (VTE) prophylaxis in joint arthroplasty in which "routine" risk patients receive a mobile compression device in conjunction with aspirin and "high"-risk patients receive warfarin for thromboprophylaxis."	3.83	The Effectiveness of a Risk Stratification Protocol for Thromboembolism Prophylaxis After Hip and Knee Arthroplasty. ( Barrack, RL; Clohisy, JC; Johnson, SR; Keeney, JA; Nam, D; Nunley, RM, 2016)
"01) the rate of transfusion, units of packed red blood cells, hemoglobin drop, and hematocrit drop compared to aspirin in both unilateral and bilateral TKA patients, without significantly decreasing venous thromboembolism events (aspirin: 3 pulmonary embolisms and 4 deep venous thrombosis; Lovenox: 3 pulmonary embolisms and 2 deep venous thrombosis)."	3.83	Rate of Transfusions After Total Knee Arthroplasty in Patients Receiving Lovenox or High-Dose Aspirin. ( Hall, KE; Nakasone, CK; Radzak, KN; Wages, JJ, 2016)
"We sought to determine the frequency of thromboembolic events (deep vein thrombosis [DVT] and symptomatic pulmonary embolism [PE]) associated with the periacetabular osteotomy in in patients receiving aspirin and mechanical compression prophylaxis."	3.80	Screening for deep vein thrombosis after periacetabular osteotomy in adult patients: is it necessary? ( Bloemke, AD; Clohisy, JC; Duncan, ST; Polkowski, GG; Schoenecker, PL, 2014)
" Geniposide and genipin were studied on venous thrombosis by oral administration."	3.79	Antithrombotic activities of aqueous extract from Gardenia jasminoides and its main constituent. ( Liu, H; Wei, SF; Yang, M; Zhang, HY, 2013)
"Our institution has used a thromboprophylaxis regimen consisting of inpatient enoxaparin and outpatient aspirin for patients at standard risk for venous thrombosis after hip and knee arthroplasty."	3.78	Inpatient enoxaparin and outpatient aspirin chemoprophylaxis regimen after primary hip and knee arthroplasty: a preliminary study. ( Anderson, BJ; Bradbury, TL; Erens, GA; Hamilton, SC; Roberson, JR; Whang, WW, 2012)
"It is safe to continue low-dose (100 mg/day) aspirin in the perioperative period as a part of multimodal prophylaxis against deep vein thrombosis."	3.78	Safety of peri-operative low-dose aspirin as a part of multimodal venous thromboembolic prophylaxis for total knee and hip arthroplasty. ( Cossetto, DJ; Goudar, A; Parkinson, K, 2012)
"To compare venous thrombosis rates among animals treated with aspirin, clopidogrel bisulfate, and ketorolac tromethamine using an anastomotic "tuck" model."	3.77	Effects of antithrombogenic agents on microvenous anastomoses in a rat model. ( Harsha, WJ; Hayden, RE; Kau, RL; Kim, N, 2011)
" Deep vein thrombosis prophylaxis consisted of oral enteric-coated aspirin, pneumatic calf compression pumps, and early ambulation in all patients unless medically contraindicated."	3.77	Thromboembolic events are uncommon after open treatment of proximal humerus fractures using aspirin and compression devices. ( Abboud, JA; Bassora, R; Warrender, WJ; Widmer, BJ, 2011)
"Our objective of the study was to address the question: "What is the efficacy of a deep venous thrombosis (DVT) and pulmonary embolus prophylaxis protocol after total knee arthroplasty (TKA) in which low-risk patients had only aspirin and mechanical devices for prophylaxis?" A multimodal approach to DVT prophylaxis using aspirin as the primary mode of chemoprophylaxis was successful in preventing DVT-related morbidity and mortality in 312 consecutive TKAs performed in low-risk patients."	3.74	Evaluation of deep venous thrombosis prophylaxis in low-risk patients undergoing total knee arthroplasty. ( Callaghan, JJ; Hoballah, JJ; Liu, SS; Warth, LC; Wells, CW, 2008)
" Patients who received low-molecular-weight heparin for prophylaxis against deep venous thrombosis had a longer time until the postoperative wound was dry than did those treated with aspirin and mechanical foot compression or those who received Coumadin (warfarin); this difference was significant on the fifth postoperative day (p = 0."	3.74	Factors associated with prolonged wound drainage after primary total hip and knee arthroplasty. ( DeWal, H; Di Cesare, PE; Patel, VP; Preston, C; Sehgal, B; Walsh, M, 2007)
"Deep vein thrombosis (DVT) remains common in patients with acute ischemic stroke (AIS) receiving aspirin and graded compression stockings (considered standard thromboprophylaxis in the UK), most events occurring in patients with Barthel indices (BI) of <9 ('severe stroke') around the time of admission."	3.72	Screening for proximal deep vein thrombosis after acute ischemic stroke: a prospective study using clinical factors and plasma D-dimers. ( Coshall, C; Hunt, BJ; Kelly, J; Lewis, RR; Moody, A; Parmar, K; Rudd, A, 2004)
"One hundred ninety-nine patients who underwent primary total hip arthroplasty and used in hospital pneumatic compression stockings and aspirin as thromboembolic prophylaxis were screened for deep venous thrombosis using duplex ultrasonography on the fourth postoperative day."	3.70	Late deep venous thrombosis and delayed weightbearing after total hip arthroplasty. ( Buehler, KO; Colwell, CW; D'Lima, DD; Petersilge, WJ; Walker, RH, 1999)
" Aspirin, 75 mg daily was given in addition to enoxaparin to women with antiphospholipid syndrome."	3.70	Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. ( Blumenfeld, Z; Brenner, B; Hoffman, R; Weiner, Z; Younis, JS, 2000)
"This retrospective study was performed to examine the influence of aspirin on the incidence of RVT in cadaveric and living-related renal transplant recipients receiving cyclosporin-based triple immunosuppression."	3.70	Low dose aspirin as prophylaxis against renal-vein thrombosis in renal-transplant recipients. ( Gray, DW; Morris, PJ; Nargund, V; Robertson, AJ, 2000)
"Warfarin treatment was associated with better liver function protection and renal function improvement than aspirin treatment."	2.90	Warfarin versus aspirin prevents portal vein thrombosis after laparoscopic splenectomy and azygoportal disconnection: A randomized clinical trial. ( Bai, DS; Jiang, GQ; Jin, SJ; Qian, JJ; Xia, BL; Ye, J; Zhang, C, 2019)
"Although venous thromboembolism is one of the leading causes of morbidity after knee arthroplasty, little data exist on the risk of deep venous thrombosis (DVT) after unicompartmental knee arthroplasty (UKA)."	2.84	Deep Venous Thrombosis Prophylaxis After Unicompartmental Knee Arthroplasty: A Prospective Study on the Safety of Aspirin. ( Boettner, F; Mayman, DJ; Pearle, AD; Schmidt-Braekling, T; Waldstein, W; Westrich, GH, 2017)
" GI bleeding was equally prevalent between the 2 dosing regimens, so patients need to be informed of this risk regardless of the ASA dose."	2.84	A Comparison of Two Dosing Regimens of ASA Following Total Hip and Knee Arthroplasties. ( Chen, AF; Feldstein, MJ; Hozack, WJ; Low, SL; Woodward, LA, 2017)
"However, more recently, the rate of deep vein thrombosis (DVT) has been reported to be approximately 10%."	2.80	Prevention of Venous Thromboembolism after Arthroscopic Knee Surgery in a Low-Risk Population with the Use of Aspirin. A Randomized Trial. ( Alaia, MJ; Garofolo, G; Jazrawi, LM; Kaye, ID; Martinez, A; Patel, DN; Strauss, EJ, 2015)
"Symptomatic or asymptomatic deep vein thrombosis (DVT) is a common complication following coronary artery bypass graft (CABG), in which less than 1% of these patients suffer from clinically evident pulmonary embolism (PE)."	2.78	Comparison of aspirin plus heparin with heparin alone on asymptomatic perioperative deep vein thrombosis in candidates for elective off-pump coronary artery bypass graft: a randomized clinical trial. ( Ali-Hasan-Al-Saegh, S; Forouzannia, SK; Mirhosseini, SJ; Mostafavi Pour Manshadi, SM; Naderi, N; Sanatkar, M, 2013)
"Documented VTE (including deep vein thrombosis or pulmonary embolism) and unprovoked VTE (no recent surgery, trauma, or cancer diagnosis) were prospectively evaluated, secondary end points of the trial."	2.73	Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. ( Buring, JE; Glynn, RJ; Goldhaber, SZ; Ridker, PM; Zee, RY, 2007)
"Aspirin was started on the day of surgery, whereas enoxaparin was started 48 hours after surgery."	2.72	VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty. ( Bottner, F; Haas, SB; Laskin, RS; Sculco, TP; Westrich, GH; Windsor, RE, 2006)
"The incidence of pulmonary embolism (PE) in all trials combined was low, with seven cases in 3818 participants."	2.66	Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. ( Badariotti, G; Chahla, J; Perrotta, C; Ramos, J, 2020)
"Venous thromboembolic disease (VTED) (deep venous thrombosis and pulmonary embolism) is a considerable source of morbidity and mortality following lower extremity total joint arthroplasty."	2.52	What's New in Venous Thromboembolic Prophylaxis Following Total Knee and Total Hip Arthroplasty? An Update. ( Cherian, JJ; Elmallah, RK; Jauregui, JJ; Mont, MA; Pierce, TP, 2015)
"Is it better to continue treatment of deep venous thrombosis or pulmonary embolism with LMWH or switch to an oral anticoagulant? What is the optimal duration of treatment? To answer these questions, we conducted a review of the literature using the standard Prescrire methodology."	2.49	Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months. ( , 2013)
"Keywords used were DVT, thromboembolism, deep vein thrombosis and air travel-related venous thromboembolism."	2.47	All I want for coagulation. ( Bridgett, MR; Nunn, KP; Walker, I; Walters, MR, 2011)
"Deep Venous Thrombosis is a common disease with fatal and serious long term burdensome complications."	2.45	Deep vein thrombosis: risk factors and prevention in surgical patients. ( Adekoya-Cole, TO; Enweluzo, GO; Giwa, SO; Obalum, DC; Ogo, CN, 2009)
"Ten patients with aneurysms and/or pseudoaneurysms and six patients with occlusive lesions have undergone surgical treatment."	2.44	Major arterial involvement and review of Behcet's disease. ( Alpagut, U; Dayioglu, E; Ugurlucan, M, 2007)
"Fatal pulmonary embolism is estimated to occur in nearly 1% of these women."	2.44	WITHDRAWN: Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. ( D'Angelo, A; Mol, B; Oates-Whitehead, RM, 2007)
" The oral immunomodulatory drugs thalidomide and lenalidomide have produced major therapeutic responses in patients with MM when used in combination with oral steroids and chemotherapy, but a high incidence of VTE has been reported."	2.43	Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. ( Hussein, MA, 2006)
"Venous thromboembolism is a common complication following a hip replacement."	2.42	Thromboprophylaxis in patients undergoing total hip replacement. ( Brenkel, IJ; Cook, RE, 2003)
"Many authors relate this factor with preeclampsia, intrauterine fetal growth retardation, spontaneous abortion, unexplained cases of still birth, placental abruption, and thromboembolic complications during and after parturition."	2.42	[Factor V Leiden mutation and pregnancy complications]. ( Abraitis, V; Mockeviciene, A; Mongirdiene, A, 2003)
"Fatal pulmonary embolism is estimated to occur in nearly 1% of these women."	2.42	Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. ( D'Angelo, A; Mol, B; Oates-Whitehead, RM, 2003)
"Venous thromboembolism is a frequent and serious disorder influenced by numerous factors."	2.42	Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. ( Dahl, OE; Mismetti, P; Quinlan, DJ; Rosencher, N; Samama, MM, 2003)
" Unfractionated heparin (UFH) and low molecular weight heparin (LMWH) do not cross the placenta and are safe for the fetus, but long-term treatment with UFH is problematic because of its inconvenient administration, the need to monitor anticoagulant activity and because of its potential side effects, such as heparin-induced thrombocytopenia and osteoporosis."	2.42	The safety of antithrombotic therapy during pregnancy. ( Ageno, W; Crotti, S; Turpie, AG, 2004)
"Aspirin has also demonstrated a potential ability to reduce the risk of deep venous thrombosis and pulmonary embolism."	2.41	An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I. ( Moyad, MA, 2001)
"Thrombosis is of greater overall clinical importance in terms of morbidity and mortality than all of the hemorrhagic disorders combined."	2.41	Antithrombotic agents: implications in dentistry. ( Henry, RG; Little, JW; McIntosh, BA; Miller, CS, 2002)
"Aspirin was first synthesised 100 years ago and its preparation and marketing is generally reckoned to have been the foundation of the pharmaceutical industry."	2.40	Platelets, aspirin, and cardiovascular disease. ( Elwood, PC; Hughes, C; O'Brien, JR, 1998)
"After the procedure, deep vein thrombosis (DVT) was a commonly diagnosed complication (3."	1.91	Incidence of venous thromboembolism in patients with peripheral arterial disease after endovascular intervention. ( Agala, C; Caruso, DM; Duchesneau, E; Farber, M; Kindell, DG; Marston, WA; Marulanda, K; McGinigle, KL, 2023)
"The incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) after total joint arthroplasty (TJA) procedures are lower in Asian populations than in Caucasian populations."	1.91	Combination of enoxaparin and low-dose aspirin for thromboprophylaxis in selective patients after primary total joint arthroplasty in a Taiwanese population. ( Chang, WL; Chen, CF; Chen, WM; Chou, TA; Pai, FY; Tsai, SW; Wu, PK, 2023)
"Similarly, thrombus weights were reduced in mice with impaired ITAM signaling (Clec2mKO + JAQ1; WT + ibrutinib) but not in Clec2mKO or WT + JAQ1 mice."	1.72	Both G protein-coupled and immunoreceptor tyrosine-based activation motif receptors mediate venous thrombosis in mice. ( Bergmeier, W; Cooley, BC; Holle, LA; Kawano, T; Lee, RH; Mackman, N; Mwiza, JMN; Nieswandt, B; Paul, DS; Schug, WJ; Wolberg, AS, 2022)
"The current rates of deep vein thrombosis (DVT) and pulmonary embolism (PE) at our institution following hip or knee arthroplasty or hip fracture surgery are 1."	1.56	Incidence of venous thromboembolism after total hip, total knee and hip fracture surgery at Waitemata District Health Board following a peer-reviewed audit. ( Andrew, P; Farrington, B; Lawes, CM; Merriman, E; Millar, JS; Misur, P; Walker, M, 2020)
"Incidence of postoperative deep venous thrombosis (DVT), pulmonary embolism (PE), bleeding-related complications, postoperative anaemia, and transfusion were identified at 2 weeks, 30 days, 6 weeks, and 90 days."	1.56	Venous thromboprophylaxis after total hip arthroplasty: aspirin, warfarin, enoxaparin, or factor Xa inhibitors? ( Amanatullah, DF; Bala, A; Burk, DR; Goodman, SB; Huddleston, JI; Maloney, WJ; Murasko, MJ, 2020)
"Geographic region, patient age, gender, deep vein thrombosis prophylaxis strategy, and complications were obtained."	1.51	Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates. ( Gottschalk, MB; Pour, AE; Roberson, JR; Runner, RP; Staley, CA, 2019)
"We report a patient who had recurrent deep vein thrombosis (DVT) as the presenting symptom of Behcet's Disease."	1.48	Recurrent Iliofemoral Venous Thrombosis in the Setting of May-Thurner Syndrome as the Presenting Symptom of Behcet's Disease. ( Chun, K; Lakha, S; Png, CYM; Ting, W, 2018)
"No thrombosis was detected."	1.48	Long-haul flights, edema, and thrombotic events: prevention with stockings and Pycnogenol® supplementation (LONFLIT Registry Study). ( Belcaro, G; Cornelli, U; Cotellese, R; Dugall, M; Feragalli, B; Hosoi, M, 2018)
"Imaging revealed an acute cerebral venous thrombosis."	1.48	CO poisoning as an associated risk factor for CVT. ( Gibb, GJ; Laghari, FJ; Phinney, TA, 2018)
"Deep venous thrombosis is one of the common complications after major surgery in the Department of Orthopedics."	1.48	Effect of different types of anticoagulants in the prevention of venous thrombosis in the operation of knee joint bone operation. ( Nie, L; Xu, W; Yang, Z; Zhang, T, 2018)
"Warfarin treatment within 12 months achieved significantly higher rates of complete recanalization than aspirin or clopidogrel in patients with PVT (54."	1.48	Portal Vein Thrombosis in Patients With Cirrhosis Undergoing Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors, Warfarin Efficacy, and Clinical Outcomes. ( Li, YH; Wu, HM; Xu, Y; Yang, J; Yang, LH; Yue-Meng, W, 2018)
"EHIT can lead to deep vein thrombosis/pulmonary embolism, which cause significant disability and, rarely, death."	1.46	Outcomes of a single-center experience with classification and treatment of endothermal heat-induced thrombosis after endovenous ablation. ( Chambers, CM; Cuff, RF; Korepta, LM; Mansour, MA; Slaikeu, JD; Watson, JJ; Wong, PY, 2017)
"Aspirin was associated with a significant protective effect in multivariate analysis, with an odds ratio of 0."	1.43	Aspirin as added prophylaxis for deep vein thrombosis in trauma: A retrospective case-control study. ( Bansal, V; Brill, JB; Calvo, RY; Lewis, PR; Shackford, SR; Sise, MJ; Wallace, JD, 2016)
"Multiple myeloma is a malignant plasma cells dyscrasia that mainly affects patients older than 65 years."	1.43	[Multiple myeloma and venous thrombosis. Which thromboprophylaxis should be given?]. ( Carrier, M; de Moreuil, C; Delluc, A; Eveillard, JR; Ianotto, JC, 2016)
"The incidence of symptomatic deep vein thrombosis and pulmonary embolism was evaluated."	1.43	Tranexamic Acid Can Be Administered to Arthroplasty Patients Who Receive Aspirin for Venous Thromboembolic Prophylaxis. ( Chen, AF; Heller, S; Parvizi, J; Secrist, E; Shahi, A, 2016)
"The rate of surgical site infection was similar between the aspirin group and the warfarin group (1."	1.43	Aspirin Can Be Used as Prophylaxis for Prevention of Venous Thromboembolism After Revision Hip and Knee Arthroplasty. ( Chen, AF; Deirmengian, GK; Heller, S; Maltenfort, M; Parvizi, J; Smith, EB, 2016)
"Most of the children (88."	1.42	Case series of thromboembolic complications in childhood nephrotic syndrome: Hacettepe experience. ( Aytac, S; Besbas, N; Cetin, M; Gumruk, F; Kara, F; Kuskonmaz, B; Tavil, B; Topaloglu, R; Unal, S, 2015)
"Incidences of symptomatic deep vein thrombosis (DVT) and PE, and major or minor bleeding complications were evaluated."	1.42	Clinical Performance of the 1st American Academy of Orthopaedic Surgeons Clinical Guideline on Prevention of Symptomatic Pulmonary Embolism after Total Knee Arthroplasty in Korean Patients. ( Cho, KJ; Fang, R; Kim, TK; Kim, YH; Na, YG, 2015)
"Thulium VapoEnucleation of the prostate seems to be a safe and efficacious procedure for the treatment of symptomatic BPO in patients at high cardiopulmonary risk on OA."	1.40	Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy. ( Bach, T; Brüning, M; Gabuev, A; Gross, AJ; Herrmann, TR; Netsch, C; Stoehrer, M, 2014)
"Cerebral venous thrombosis is a rare condition with various clinical presentations which may delay diagnosis."	1.40	Thrombosis of the great cerebral vein in a hemodialysis patient. ( Basic-Jukic, N; Gledovic, B; Radunovic, D; Ratkovic, M, 2014)
"Lenalidomide has significant antimyeloma activity but it is associated with a significant risk of venous thromboembolism (VTE)."	1.39	Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. ( Bagratuni, T; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kanelias, N; Kastritis, E; Kostouros, E; Politou, M; Roussou, M; Terpos, E, 2013)
"270 patients (93 with deep vein thrombosis (DVT) or pulmonary embolism (PE), and 177 with non-haemorrhagic stroke (cerebrovascular accident (CVA)) admitted between January 2006 and December 2010 with a discharge diagnosis of either DVT, PE or CVA, who had LAC and antiphospholipid antibodies measured within 6 months from their index admission."	1.38	High antiphospholipid antibody levels are associated with statin use and may reflect chronic endothelial damage in non-autoimmune thrombosis: cross-sectional study. ( Broder, A; Putterman, C; Tobin, JN, 2012)
"Case 2: Three-yr-old boy with IgA deficiency and liver disease."	1.38	Budd-Chiari syndrome in children and outcome after liver transplant. ( Cipriano, A; Furtado, E; Gomes, AC; Gonçalves, I; Pinto, C; Rubino, G, 2012)
"The rate of VTE, pulmonary embolism, proximal deep vein thrombosis (DVT) and distal DVT was 1."	1.38	Aspirin for elective hip and knee arthroplasty: a multimodal thromboprophylaxis protocol. ( Esposito, A; Gesell, M; Gonzalez Della Valle, A; Ma, Y; Memtsoudis, SG; Vulcano, E, 2012)
"Incidence of postoperative hemorrhage (early and delayed) was not significant (P = ."	1.37	Stopping anticoagulation before TURP does not appear to increase perioperative cardiovascular complications. ( Bariol, SV; Brooks, AJ; Drummond, M; Lau, HM; McDonald, C; Patel, MI; Raj, MD; Wang, AC; Woo, HH, 2011)
"Diabetes mellitus is associated with platelet hyperactivity, which leads to increased morbidity and mortality from cardiovascular disease."	1.37	Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. ( Capone, M; Di Febbo, C; Evangelista, V; Fava, C; Gleim, S; Hwa, J; Levantesi, G; Martin, K; Minuz, P; Patrignani, P; Porreca, E; Rade, J; Stitham, J; Tacconelli, S; Tang, WH; Wen, L, 2011)
"To determine prevalence of central vein stenosis following catheterization with double-lumen temporary catheters, we performed color Doppler sonography in 100 consecutive patients."	1.36	Prevalence of central vein stenosis following catheterization in patients with end-stage renal disease. ( Naroienejad, M; Rezvani, A; Saedi, D, 2010)
" Dosing of IV UFH should prolong the activated partial thromboplastin time (aPTT) to a range that corresponds to an anti-factor Xa assay (anti-FXa) level of 0."	1.35	Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). ( Chalmers, E; Chan, A; deVeber, G; Kirkham, F; Massicotte, P; Michelson, AD; Monagle, P, 2008)
"Deep venous thrombosis (DVT) and pulmonary embolism (PE) cause significant morbidity and mortality in orthopaedic surgical practice, although the incidence following surgery to the lumbosacral spine is less than following lower limb surgery."	1.35	Incidence of thromboembolic complications in lumbar spinal surgery in 1,111 patients. ( Craig, N; Nicol, M; Sun, Y; Wardlaw, D, 2009)
"Local thrombolysis of deep vein thrombosis with ultrasound surveillance is, in indicated patients, a safe method even if a vein injury occurs."	1.35	[Repeated local thrombolysis in a patient with axillary and subclavian vein injury and thrombosis]. ( Hofírek, I; Sárník, S, 2009)
"The classical clinical picture of antiphospholipid antibody syndrome (APS) is characterized by venous and arterial thrombosis, fetal losses and thrombocytopenia in the presence of anticardiolipin antibodies and/or lupus anticoagulant."	1.35	Paediatric case report: primary antiphospholipid syndrome presented with non-thrombotic neurological picture psychosis; treat by antidepressants alone? ( Alhumayed, S; Alshehri, A; Shabana, M; Shalaby, M, 2009)
"Twenty patients in each group had deep venous thrombosis (7% and 5."	1.34	Symptomatic thromboembolism after one-stage bilateral THA with a multimodal prophylaxis protocol. ( Anderson, J; Beksaç, B; González Della Valle, A; Salvato, EA; Sculco, TP; Sharrock, NE, 2007)
"Clinically symptomatic deep venous thrombosis was detected in association with four (0."	1.34	Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment. ( Boutary, M; Dorr, LD; Gendelman, V; Long, WT; Maheshwari, AV; Wan, Z, 2007)
"Nonfatal pulmonary embolisms were diagnosed in 17 (0."	1.33	Thromboembolic disease prophylaxis in total hip arthroplasty. ( Goswami, A; Sarmiento, A, 2005)
"(2) Aspirin has been tested in several placebo-controlled trials and has a positive risk-benefit balance, preventing about 5 deaths per 1000 patients with ischaemic stroke."	1.33	Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin. ( , 2005)
"Antiphospholipid syndrome is a recognized disorder of pregnancy."	1.33	Maternal and fetal complications of antiphospholipid syndrome: a case report with long-term follow-up. ( Khurshid, M; Naru, T; Nazir, Z, 2006)
"As the problem of morbid obesity has increased over the past several years in the United States, gastric bypass has become a viable option for many people seeking treatment."	1.33	Preventing vascular complications after gastric bypass. ( Heffline, MS, 2006)
"Data indicate that deep venous thrombosis (DVT) occurs at the time of knee arthroplasty."	1.32	A multimodality regimen for deep venous thrombosis prophylaxis in total knee arthroplasty. ( Emerson, RH; Higgins, LL; Reitman, RD; Tarbox, TR, 2003)
"Early administration of a combined regimen of clopidogrel and aspirin following off-pump CABG is safe and is associated with a relatively low incidence of major adverse cardiac events, bleeding, PE, and DVT."	1.32	A feasibility study of the safety and efficacy of a combined clopidogrel and aspirin regimen following off-pump coronary artery bypass grafting. ( Benhameid, O; Endo, M; Shennib, H, 2003)
"Protein C and protein S deficiency were found in nine and two patients, respectively."	1.32	Venous thrombosis among patients with AIDS. ( Corona-de la Peña, N; de Chávez-Ochoa, AR; Majluf-Cruz, A; Montiel-Manzano, G; Nieto-Cisneros, L; Sánchez-Barboza, R; Santoscoy-Gómez, M; Silva-Estrada, M; Treviño-Pérez, S, 2004)
"Treatment with aspirin+heparin alone reduced thrombus weight by 37+/-25% (18."	1.32	Augmentation of in-stent clot dissolution by low frequency ultrasound combined with aspirin and heparin. An ex-vivo canine shunt study. ( Atar, S; Birnbaum, Y; Horzewski, M; Kaul, S; Kobal, S; Luo, H; Miyamoto, T; Neuman, Y; Rukshin, V; Siegel, RJ; Thompson, T; Tsang, V, 2003)
"The prevalence of all VTE, proximal deep vein thrombosis (PDVT), and pulmonary embolism (PE) after 21 days were 40%, 18%, and 12%, increasing to 63%, 30%, and 20% in patients with Barthel indices (BI) of < or =9 2 days after stroke (BI-2< or =9)."	1.32	Venous thromboembolism after acute ischemic stroke: a prospective study using magnetic resonance direct thrombus imaging. ( Coshall, C; Hunt, BJ; Kelly, J; Lewis, RR; Moody, A; Rudd, A, 2004)
"Two (2."	1.31	Isolated internal jugular vein thrombosis: risk factors and natural history. ( Deitcher, SR; Sheikh, MA; Topoulos, AP, 2002)
"Thirty-nine patients with deep vein thrombosis, 28 with arteriosclerosis obliterans, and 10 with pulmonary embolism were the subjects of this study."	1.31	Clinical assessment of vascular thrombosis using indium-111 platelet scintigraphy. ( Morimoto, Y; Mukai, T; Okada, M; Sugimoto, T, 2000)
"Patients with antiphospholipid antibody syndrome (APS) have a high risk for rethrombosis."	1.31	Longterm anticoagulation is preferable for patients with antiphospholipid antibody syndrome. result of a decision analysis. ( Brunner, HI; Chan, WS; Feldman, BM; Ginsberg, JS, 2002)
"Venous thrombosis was reduced 56% by oral soluble acetylsalicylic acid and 27% by oral aspirin."	1.30	Some effects of prophylactic aspirins and heparins on concurrent arterial and venous thrombosis in the same animal. ( Iomhair, MM; Lavelle, SM, 1998)
"Deep venous thrombosis was diagnosed after seven procedures (0."	1.30	Thromboembolic prophylaxis with use of aspirin, exercise, and graded elastic stockings or intermittent compression devices in patients managed with total hip arthroplasty. ( Goswami, AD; Sarmiento, A, 1999)

Research

Studies (316)

Authors

Clinical Trials (35)

Trial Overview

Trial Outcomes

Number of Participants Experiencing a Venous Thromboembolism

Number of Participants With at Least One Adverse Event

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	10 (3.16)	18.2507
2000's	162 (51.27)	29.6817
2010's	113 (35.76)	24.3611
2020's	31 (9.81)	2.80

Authors	Studies
Batra, S	1
Srinivasan, T	1
Rastogi, SK	1
Kundu, B	1
Patra, A	1
Bhaduri, AP	1
Dixit, M	1
Hou, M	1
Lv, M	2
Zhang, X	1
Wang, Y	2
Zhao, S	1
Wu, J	1
Peng, S	1
Zhao, M	1
Kirchner, VA	1
O'Farrell, B	1
Imber, C	1
McCormack, L	1
Northup, PG	1
Song, GW	1
Spiro, M	1
Raptis, DA	1
Durand, F	1
Mwiza, JMN	1
Lee, RH	1
Paul, DS	1
Holle, LA	1
Cooley, BC	1
Nieswandt, B	1
Schug, WJ	1
Kawano, T	1
Mackman, N	1
Wolberg, AS	1
Bergmeier, W	1
Li, Y	2
Fu, X	1
Liu, P	1
Liu, S	1
Pan, Y	1
Metcalf, KB	1
Du, JY	1
Ochenjele, G	1
Pires da Rosa, G	1
Ferreira, E	1
Sousa-Pinto, B	1
Rodríguez-Pintó, I	1
Brito, I	1
Mota, A	1
Cervera, R	2
Espinosa, G	2
Kindell, DG	1
Marulanda, K	1
Caruso, DM	1
Duchesneau, E	1
Agala, C	1
Farber, M	1
Marston, WA	1
McGinigle, KL	1
Engler, ID	3
Maximiliano, CL	1
Jaime, GC	1
Erika, MH	1
O'Toole, RV	1
Stein, DM	1
O'Hara, NN	1
Frey, KP	1
Taylor, TJ	1
Scharfstein, DO	1
Carlini, AR	1
Sudini, K	1
Degani, Y	1
Slobogean, GP	1
Haut, ER	1
Obremskey, W	1
Firoozabadi, R	1
Bosse, MJ	1
Goldhaber, SZ	3
Marvel, D	1
Castillo, RC	1
Agarwal, AR	1
Das, A	1
Harris, A	1
Campbell, JC	1
Golladay, GJ	1
Thakkar, SC	1
Rosenberg, K	1
Chaudhry, H	1
Sohal, A	1
Dukovic, D	1
Kohli, I	1
Sharma, R	1
Singla, P	1
Prajapati, D	1
Yang, J	2
Poacher, AT	1
Hoskins, HC	1
Protty, MB	1
Pettit, R	1
Johansen, A	1
Tsai, SW	1
Chang, WL	1
Pai, FY	1
Chou, TA	1
Chen, CF	1
Wu, PK	1
Chen, WM	1
Meng, J	1
Liu, W	1
Xiao, Y	1
Tang, H	1
Wu, Y	1
Gao, S	1
Liu, HZ	1
Liang, J	1
Hu, AX	1
Du, ZQ	1
Zhao, JZ	1
Dong, J	1
Bi, JB	1
Ren, YF	1
Zhang, J	1
Khalid, B	1
Wu, Z	1
Lv, Y	1
Zhang, XF	1
Wu, RQ	1
Jastifer, J	1
Manson, W	1
Smith, B	1
Cooper, MT	1
Brigido, SA	1
Hunter, AM	1
Montgomery, TP	1
Pitts, CC	1
Moraes, L	1
Anderson, M	1
Wilson, J	1
McGwin, G	1
Shah, A	1
Millar, JS	1
Lawes, CM	1
Farrington, B	1
Andrew, P	1
Misur, P	1
Merriman, E	1
Walker, M	1
Perrotta, C	1
Chahla, J	1
Badariotti, G	1
Ramos, J	1
Lal, S	1
Hashmi, J	1
Chan, NC	2
Weitz, JI	2
Le, G	1
Yang, C	1
Zhang, M	1
Xi, L	1
Luo, H	2
Tang, J	1
Zhao, J	1
Gangat, N	1
Tefferi, A	1
Hughes, LD	1
Lum, J	1
Mahfoud, Z	1
Malik, RA	1
Anand, A	1
Charalambous, CP	1
Chen, B	1
Hu, N	1
Shoji, K	1
Zen, K	1
Ookura, T	1
Yanishi, K	1
Matoba, S	1
McIntire, SC	1
Bernstein, EM	1
Tompane, TM	1
Briggs, AM	1
Ferris, WJ	1
Renninger, CH	1
McDonald, LS	1
Hurvitz, AP	1
Bravo-Perez, C	1
Fernández-Caballero, M	1
Soler-Espejo, E	1
Garcia-Torralba, E	1
Sorigue, M	1
García-Malo, MD	1
Jerez, A	1
Vicente, V	1
Roldán, V	1
de Arriba, F	1
Korepta, LM	1
Watson, JJ	1
Mansour, MA	1
Chambers, CM	1
Cuff, RF	1
Slaikeu, JD	1
Wong, PY	1
Snyder, MA	2
Sympson, AN	2
Zan, P	1
Li, G	1
Bala, A	2
Huddleston, JI	2
Goodman, SB	2
Maloney, WJ	2
Amanatullah, DF	2
Cafri, G	1
Paxton, EW	1
Chen, Y	1
Cheetham, CT	1
Gould, MK	1
Sluggett, J	1
Bini, SA	1
Khatod, M	1
Gupta, E	1
Siddiqi, FS	1
Kunjal, R	1
Faisal, M	1
Al-Saffar, F	1
Bajwa, AA	1
Jones, LM	1
Seeram, V	1
Cury, JD	1
Shujaat, A	1
Jones, CW	1
Spasojevic, S	1
Goh, G	1
Joseph, Z	1
Wood, DJ	1
Yates, PJ	1
Sindhu, KK	1
Cohen, B	1
Blood, T	1
Gil, JA	1
Owens, B	1
Wan, YM	1
Li, YH	2
Wu, HM	2
Xu, ZY	1
Xu, Y	2
Yang, LH	2
Wu, XN	1
Yang, JH	1
Goel, R	1
Fleischman, AN	1
Tan, T	1
Sterbis, E	1
Huang, R	2
Higuera, C	1
Parvizi, J	4
Rothman, RH	2
Lakha, S	1
Png, CYM	1
Chun, K	1
Ting, W	1
Belcaro, G	2
Cornelli, U	2
Dugall, M	2
Hosoi, M	2
Cotellese, R	2
Feragalli, B	2
Phinney, TA	1
Gibb, GJ	1
Laghari, FJ	1
Sobh, AH	1
Koueiter, DM	1
Mells, A	1
Siljander, MP	1
Karadsheh, MS	1
Faour, M	1
Piuzzi, NS	1
Brigati, DP	1
Klika, AK	1
Mont, MA	2
Barsoum, WK	1
Higuera, CA	1
Xu, W	1
Zhang, T	1
Yang, Z	1
Nie, L	1
Hu, S	1
Ledda, A	1
Corsi, M	1
Ricci, A	1
Ippolito, E	1
Errichi, BM	1
Cesarone, MR	1
Bawa, H	1
Weick, JW	1
Dirschl, DR	1
Luu, HH	1
Peñaloza-Martínez, E	1
Demelo-Rodríguez, P	1
Proietti, M	1
Soria Fernández-Llamazares, G	1
Llamazares-Mendo, C	1
Álvarez-Sala Walther, L	1
Marra, AM	1
Del Toro-Cervera, J	1
Woon, CYL	1
Shah, RR	1
Pardi, BM	1
Schwartz, BE	1
Goldstein, JM	1
Cipparrone, NE	1
Goldstein, WM	1
Runner, RP	1
Gottschalk, MB	1
Staley, CA	1
Pour, AE	1
Roberson, JR	2
Bai, DS	2
Xia, BL	2
Zhang, C	1
Ye, J	1
Qian, JJ	2
Jin, SJ	2
Jiang, GQ	2
Mihara, M	1
Tamaki, Y	1
Nakura, N	1
Takayanagi, S	1
Saito, A	1
Ochiai, S	1
Hirakawa, K	1
Cohen, AT	3
Bauersachs, R	1
Mai, V	1
Bertoletti, L	1
Cucherat, M	1
Jardel, S	1
Grange, C	1
Provencher, S	1
Lega, JC	1
Ghosh, A	1
Best, AJ	1
Rudge, SJ	1
Chatterji, U	1
Murasko, MJ	1
Burk, DR	1
Greenberg, B	1
Neaton, JD	1
Anker, SD	1
Byra, WM	1
Cleland, JGF	1
Deng, H	2
Fu, M	1
La Police, DA	1
Lam, CSP	1
Mehra, MR	1
Nessel, CC	1
Spiro, TE	1
van Veldhuisen, DJ	1
Vanden Boom, CM	1
Zannad, F	1
Zou, P	1
Li, H	1
Cai, J	1
Li, C	1
Chen, Z	1
Li, X	1
Mirhosseini, SJ	1
Forouzannia, SK	1
Mostafavi Pour Manshadi, SM	1
Ali-Hasan-Al-Saegh, S	1
Naderi, N	1
Sanatkar, M	1
Netsch, C	1
Stoehrer, M	1
Brüning, M	1
Gabuev, A	1
Bach, T	1
Herrmann, TR	1
Gross, AJ	1
Bagratuni, T	1
Kastritis, E	1
Politou, M	1
Roussou, M	1
Kostouros, E	1
Gavriatopoulou, M	1
Eleutherakis-Papaiakovou, E	1
Kanelias, N	1
Terpos, E	1
Dimopoulos, MA	1
Kulshrestha, V	1
Kumar, S	2
Raphael, IJ	1
Tischler, EH	1
Hozack, WJ	2
Allen, G	1
Ratkovic, M	1
Basic-Jukic, N	1
Gledovic, B	1
Radunovic, D	1
Prandoni, P	2
Barbar, S	1
Milan, M	1
Vedovetto, V	1
Pesavento, R	1
Faustino, EV	1
Hanson, S	1
Spinella, PC	1
Tucci, M	1
O'Brien, SH	1
Nunez, AR	1
Yung, M	1
Truemper, E	1
Qin, L	1
Li, S	1
Marohn, K	1
Randolph, AG	1
Diez-Ewald, M	1
Zou, Y	1
Tian, S	1
Sun, K	1
Polkowski, GG	1
Duncan, ST	1
Bloemke, AD	1
Schoenecker, PL	1
Clohisy, JC	2
Gist, KM	1
Chima, RS	1
Panos, GD	1
Panos, LD	1
Hafezi, F	1
Gatzioufas, Z	1
Tavil, B	1
Kara, F	1
Topaloglu, R	1
Aytac, S	1
Unal, S	1
Kuskonmaz, B	1
Cetin, M	1
Besbas, N	1
Gumruk, F	1
Lawall, H	1
Oberacker, R	1
Zemmrich, C	1
Bramlage, P	1
Diehm, C	1
Schellong, SM	1
Cho, EH	1
Ligh, C	1
Hodulik, KL	1
Hollenbeck, ST	1
Stiefelhagen, P	2
Aboyans, V	1
Brodmann, M	1
De Carlo, M	1
Clement, D	1
Mazzolai, L	1
van Bortel, L	1
van Sambeek, MR	1
Vlachopoulos, C	1
Schrör, K	1
Pierce, TP	1
Elmallah, RK	1
Jauregui, JJ	1
Cherian, JJ	1
Oo, W	1
Kozikowski, A	1
Stein, J	1
Lolis, J	1
Pekmezaris, R	1
Makaryus, AN	1
Wolf-Klein, G	1
Dimitrova, V	1
Dimitrov, R	1
Savov, A	1
Hayek, S	1
Batura, D	1
Thompson, R	1
Thachil, J	1
Kaye, ID	1
Patel, DN	1
Strauss, EJ	1
Alaia, MJ	1
Garofolo, G	1
Martinez, A	1
Jazrawi, LM	1
Braithwaite, I	1
Dunbar, L	1
Eathorne, A	1
Weatherall, M	1
Beasley, R	1
Na, YG	1
Fang, R	1
Kim, YH	1
Cho, KJ	1
Kim, TK	1
Nam, D	2
Nunley, RM	1
Johnson, SR	1
Keeney, JA	1
Barrack, RL	2

Trial	Phase	Enrollment	Study Type	Start Date	Status
Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy[NCT04352439]	Phase 4	19 participants (Actual)	Interventional	2020-08-08	Completed
Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial[NCT04696120]	Phase 2	200 participants (Anticipated)	Interventional	2021-03-02	Not yet recruiting
A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban With Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Diseas[NCT01877915]	Phase 3	5,081 participants (Actual)	Interventional	2013-09-10	Completed
A Different Approach to Preventing Thrombosis (ADAPT): A Randomized Controlled Trial Comparing Low Molecular Weight Heparin to Acetylsalicylic Acid in Orthopedic Trauma Patients[NCT02774265]	Phase 3	329 participants (Actual)	Interventional	2016-01-31	Completed
REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145]	Phase 4	40 participants (Actual)	Interventional	2020-06-23	Completed
Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes[NCT02556203]	Phase 3	1,653 participants (Actual)	Interventional	2015-12-16	Terminated (stopped due to Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator)
Swelling Management After Total Knee Arthroplasty[NCT04841356]		21 participants (Actual)	Interventional	2021-04-01	Completed
Efficacy of Prolonged Distal Calf Compression as Part of a Multimodal DVT Protocol in Tourniquet-less Total Knee Arthroplasty: a Randomized Clinical Trial in 100 Patients[NCT02102828]		100 participants (Actual)	Interventional	2014-03-31	Completed
Evaluation of Portal Venous System Thrombosis After Blunt Splenic Trauma Utilizing Doppler Ultrasound[NCT01906983]		80 participants (Anticipated)	Observational [Patient Registry]	2013-07-31	Recruiting
Thrombosis in Newly Diagnosed Multiple Myeloma Patients: a Clinical Audit of Intermediate Dose Low Molecular Weight Heparin[NCT05541978]		140 participants (Actual)	Observational	2022-09-01	Completed
A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS[NCT00551928]	Phase 3	402 participants (Actual)	Interventional	2007-06-30	Active, not recruiting
Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454]	Phase 3	105 participants (Anticipated)	Interventional	2014-04-30	Recruiting
Aspirin After Six Months or One Year of Oral Anticoagulants for the Prevention of Recurrent Venous Thromboembolism in Patients With Idiopathic Venous Thromboembolism. The WARFASA Study.[NCT00222677]	Phase 2/Phase 3	70 participants (Anticipated)	Interventional	2004-05-31	Active, not recruiting
Prasugrel in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients[NCT04445623]	Phase 3	128 participants (Anticipated)	Interventional	2020-07-31	Not yet recruiting
Multicenter Randomized, Double-blind, Placebo-controlled, Clinical Trial of Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients (Asperum)[NCT04808895]	Phase 3	204 participants (Anticipated)	Interventional	2021-04-01	Not yet recruiting
Clinically-Important Venous Thromboembolism Following Lower Extremity Fractures: Epidemiology & Prevention[NCT00187408]	Phase 4	700 participants	Interventional	2002-08-31	Completed
Effect of Anticoagulation in Reducing the Incidence of Splenic/Portal Vein Thrombosis Post-Laparoscopic Splenectomy Protocol Number: 5698[NCT00769873]	Phase 2	35 participants (Actual)	Interventional	2006-10-31	Terminated (stopped due to Recruitment was slower than anticipated. Insufficient funding to expand to multi-centered trial.)
A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796]	Phase 3	1,473 participants (Actual)	Interventional	2006-12-31	Active, not recruiting
Multiple Algorithms System Of All Scores in Embolism - MOSE[NCT02911012]		15,208 participants (Anticipated)	Observational	2016-10-31	Recruiting
Toronto Thromboprophylaxis Patient Safety Initiative (TOPPS): A Cluster Randomized Trial[NCT01869075]		1,895 participants (Actual)	Interventional	2006-07-31	Completed
Multi-Screen Electronic Alert for Venous Thromboembolism Prevention[NCT00550082]		880 participants (Actual)	Observational	2007-07-31	Completed
The Protective Effect of Transcutaneous Electrical Acupoint Stimulation (TEAS) on Aged Patients Undergoing Lower Extremity Arthroplasty: A Single-Center, Double-Blinded, Randomised Controlled Trial[NCT02979028]		300 participants (Anticipated)	Interventional	2017-05-01	Not yet recruiting
Norwegian Intensive Care Unit Dalteparin Effect Study[NCT01721928]		70 participants (Actual)	Observational	2012-12-03	Completed
The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients[NCT00531843]	Phase 2/Phase 3	105 participants (Actual)	Interventional	2007-12-31	Completed
[NCT00000614]	Phase 3	0 participants	Interventional	1998-09-30	Completed
The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery[NCT02684851]	Phase 3	87 participants (Actual)	Interventional	2012-10-31	Completed
The Blood Saving Effect and Wound-related Complications of Tranexamic Acid in Mininally Invasive Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis[NCT02458729]	Phase 4	294 participants (Actual)	Interventional	2012-08-31	Completed
Phase 4 Study of Postoperative Prostaglandin E1 in Head and Neck Microsurgery[NCT00733434]	Phase 4	242 participants (Anticipated)	Interventional	2008-07-31	Recruiting
A Multicenter, Open-Label, Phase III, Randomized, Active-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of rhuMAb VEGF (Bevacizumab), in Combination With Capecitabine Chemotherapy, in Subjects With Previously Treated Metastatic Bre[NCT00109239]	Phase 3	0 participants	Interventional	2000-11-30	Completed
A Phase III, Multicenter, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab) in Combination With Standard Chemotherapy in Subjects With Metastatic Colorectal Cancer[NCT00109070]	Phase 3	0 participants	Interventional	2000-09-30	Completed
A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab), a Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor, in Combination With 5-[NCT00109226]	Phase 2	0 participants	Interventional	2000-08-31	Completed
Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women[NCT00000479]	Phase 3	39,876 participants (Actual)	Interventional	1992-09-30	Completed
Influence of Tourniquet Use and Surgery Duration on the Incidence of Deep Vein Thrombosis in Total Knee Arthroplasty[NCT01559532]		78 participants (Actual)	Observational	2008-02-29	Completed
Effects on Bleeding in Knee Arthroplasty After Ischemic Preconditioning With Sevoflurane[NCT03379103]		30 participants (Actual)	Interventional	2018-02-02	Completed
Detection of Asymptomatic Venous Thrombosis in Gynecological Patients With Pelvic Masses[NCT03260270]		60 participants (Anticipated)	Observational [Patient Registry]	2017-09-30	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	Participants (Count of Participants)
Aspirin	4

Adverse events will only include those that are determined to be related to the study drug. (NCT04352439)
Timeframe: Up to six months

Event Rate of All-Cause Mortality (ACM) or Re-Hospitalization for Worsening Heart Failure

Intervention	Participants (Count of Participants)
Aspirin	0

Event rate of all-Cause Mortality (ACM) or re-Hospitalization for worsening heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)

Event Rate of All-Cause Mortality, Myocardial Infarction (MI), or Stroke

Intervention	Event rate per 100 patient-year (Number)
Rivaroxaban	24.84
Placebo	24.57

Event Rate of all-cause mortality (ACM), MI, or stroke were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 patient [pt]-year [yr]) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)

Event Rate of Bleeding Events That Requiring Hospitalization

Intervention	Event rate per 100 patient-year (Number)
Rivaroxaban	13.44
Placebo	14.27

Event rate of bleeding events and required Hospitalization were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks

Event Rate of Cardio Vascular Death

Intervention	Event rate per 100 patient-year (Number)
Rivaroxaban	1.52
Placebo	1.16

Event rate of cardio vascular death were assessed. CV death included deaths due to spontaneous bleeding, MI, stroke, worsening HF and arrhythmias, death due to CV procedures and sudden death. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)

Event Rate of Cardio Vascular Death or Re-Hospitalization for Worsening of Heart Failure (RHHF)

Intervention	Event rate per 100 patient-year (Number)
Rivaroxaban	9.46
Placebo	9.96

Event rate of cardio vascular (CV) death or re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)

Event Rate of International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding Event

Intervention	Event rate per 100 patient-year (Number)
Rivaroxaban	23.32
Placebo	23.46

Event rate of ISTH major bleeding event were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks

Event Rate of Re-Hospitalization for Cardio Vascular Events (RHCV)

Intervention	Event rate per 100 patient-year (Number)
Rivaroxaban	2.04
Placebo	1.21

Event rate due to cardio vascular events were assessed. Hospitalization for a CV Event required that participants be hospitalized (in-patient or emergency department) for greater than 24 hours and must have met the following criterion:Discharge summary with primary reason for admission listed as CV in nature (example, bleeding, arrhythmia, ACS, MI) other than HF which was captured in the HF re-hospitalization. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)

Event Rate of Re-Hospitalization for Worsening of Heart Failure

Intervention	Event rate per 100 patient-year (Number)
Rivaroxaban	13.30
Placebo	14.04

Event rate of re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)

Event Rate of Either Fatal Bleeding or Bleeding Into a Critical Space With Potential for Permanent Disability

Intervention	Event rate per 100 patient-year (Number)
Rivaroxaban	17.24
Placebo	17.45

Event rate of either fatal bleeding or bleeding into critical space with potential for permanent disability were assessed. Fatal bleeding event was death within 7 days after a bleeding event which required hospitalization or met International Society on Thrombosis and Haemostasis(ISTH) major bleeding definition criteria. Fatal bleeding events included those met criteria in 3 categories: 1: Any ISTH major bleeding event consider primary cause of death by investigator; 2: Any ISTH major bleeding event not considered to be primary cause of death by investigator but resulted in death within 7 days;3: Any bleeding event resulted in hospital stay and death within 7 days. Bleeding into critical space with potential for permanent disability included 7 critical spaces: intracranial, intraspinal, intraocular. Event rate estimated based on time to first occurrence of event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks

Number of Participants With Deep Venous Thromboembolism

Intervention	Event rate per 100 patient-year (Number)
	Fatal Bleeding	Critical Space Bleeding with Permanent Disability
Placebo	0.22	0.48
Rivaroxaban	0.22	0.32

DVT and how the diagnosis was made will be recorded. The number of events in participants in each arm will be compared to evaluate efficacy. (NCT02774265)
Timeframe: 90 days

Number of Participants With Pulmonary Embolism Events

Number of Participants With Treatment-related Bleeding Events as Assessed by the Need for Blood Transfusions and Procedures for Bleeding Complications After Initiation of the Study Medication.

Intervention	Participants (Count of Participants)
VTE Prophylaxis With Enoxaparin 30mg BID	5
VTE Prophylaxis With Aspirin 81mg BID	9

Intervention	Participants (Count of Participants)
VTE Prophylaxis With Enoxaparin 30mg BID	6
VTE Prophylaxis With Aspirin 81mg BID	2

Includes a greater than 2g/dL drop in hemoglobin, blood transfusion, hematoma evacuation, re-operation for a deep surgical site infection or minor procedure for bleeding and GI bleed (NCT02774265)
Timeframe: 90 days

Number of Participants With Cardiovascular Death or Thromboembolic Event

Intervention	Participants (Count of Participants)
VTE Prophylaxis With Enoxaparin 30mg BID	52
VTE Prophylaxis With Aspirin 81mg BID	53

Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication). (NCT02556203)
Timeframe: Through study completion, on average 16 months

Number of Participants With Composite Bleeding Endpoint of BARC (Bleeding Academic Research Consortium) 2, 3, or 5 Bleeds

Intervention	Participants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)	83
Antiplatelet	68

Composite of BARC 2,3 or 5 bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months

Number of Participants With Death or First Thromboembolic Event (DTE)

Intervention	Participants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)	148
Antiplatelet	85

Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 14 months

Number of Participants With Death or First Thromboembolic Event (DTE)

Intervention	Participants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)	68
Antiplatelet	63

Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeds

Intervention	Participants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)	105
Antiplatelet	78

ISTH major bleeds (NCT02556203)
Timeframe: Through study completion, on average 16 months

Number of Participants With Net-clinical Benefit

Intervention	Participants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)	49
Antiplatelet	30

The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety). (NCT02556203)
Timeframe: Through study completion, on average 16 months

Number of Participants With Primary Bleeding Event (PBE)

Intervention	Participants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)	137
Antiplatelet	100

PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding. (NCT02556203)
Timeframe: Through study completion, on average 16 months

Number of Participants With TIMI (Thrombolysis In Myocardial Infarction) Major / Minor Bleeds

Intervention	Participants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)	46
Antiplatelet	31

Composite of TIMI major and minor bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months

Percentage of Patients Prescribed Appropriate VTE Prophylaxis

Intervention	Participants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)	42
Antiplatelet	24

"Rates of appropriate VTE prophylaxis were determined as the number of patients who received VTE prophylaxis as a proportion of the number of patient at risk.~Rates reported are for the active phases (phase 1 and phase 2) and compare intervention to control.~Appropriate VTE prophylaxis was defined as:~in Hip Fracture Surgery - evidence-based VTE prophylaxis ordered within 24 of admission, restarted within 24 hours after surgery and continued for at least 10 days post-discharge in Major General Surgery - evidence-based VTE prophylaxis ordered within 24 hours post-surgery and continued for the duration of hospital stay in Acute Medical Illness - evidence-based VTE prophylaxis ordered within 24 hours of admission and continued for the duration of hospital stay.~Evidence-based VTE prophylaxis was determined to be according to the American College of Chest Physicians (ACCP) guidelines. The 9th version was the most current version at the time of the study." (NCT01869075)
Timeframe: End of study (end of phase 2) - measured over duration of hospital stay.

Increased Bleeding Attributed to Fondaparinux

Intervention	percentage of patients (Number)
AMI - Knowledge Translation Toolkit	64
AMI - Usual Care	62
MGS - Knowledge Translation Toolkit	67
MGS - Usual Care	54
HFS - Knowledge Translation Toolkit	85
HFS - Usual Care	76

Coagulopathic bleeding due to fondaparinux was suspected in patients requiring packed red cell transfusions after initiation of fondaparinux therapy only if the change in hematocrit prompting transfusion was not clinically commensurate with the degree of injuries that the patient had sustained (primarily orthopaedic) and/or the hematocrit did not respond appropriately post-transfusion. (NCT00531843)
Timeframe: 3 weeks post injury

Normal Trough and Peak Fondaparinux Concentration

Intervention	participants (Number)
Fondaparinux Sodium	0

Serum samples were collected 30 minutes before (trough) and 2 hours after (peak) the third dose of fondaparinux. Normative data plots comparing study participants with healthy volunteers were supplied by the company outsourced to analyze samples. (NCT00531843)
Timeframe: Day 3

Presence of Deep Vein Thrombosis (DVT) or Pulmonary Embolus (PE)

Intervention	Participants (Number)
	Trough values outside normative range	Peak values outside normative range
Fondaparinux Sodium	0	0

Color-flow duplex venous ultrasonography examinations of upper and lower extremities were performed within 48 hours of injury, and then weekly until discharge or 3 weeks. DVT was defined as any clot occurring in the subclavian, iliac, femoral, or popliteal location. Patients were examined daily for clinical signs and symptoms of venous thromboembolism (VTE) and PE. Small, nonocclusive clots discovered in other locations were observed for progression on sequential ultrasonography examinations. (NCT00531843)
Timeframe: within 3 weeks post injury

Allogenic Blood Transfusion Rates

Intervention	participants (Number)
	DVT	DVT after fondaparinux	PE
Fondaparinux Sodium	2	1	0
No Fondaparinux	2	NA	0

Number of participant received allogenic blood transfusions. (NCT02684851)
Timeframe: post-operative

Estimate Blood Loss

Intervention	Participants (Count of Participants)
Tranexamic	21
Placebo	13

To measure average estimate perioperative blood loss (NCT02684851)
Timeframe: perioperative

Number of Participants With a Thromboembolic Event

Intervention	mL (Mean)
Tranexamic	727.6
Placebo	560.1

Do patients undergoing acetabular ORIF who receive tranexamic acid have a higher risk for thromboembolic events than patients who receive placebo? (NCT02684851)
Timeframe: 30 days

Units of Packed Red Blood Cells Transfused

Intervention	Participants (Count of Participants)
Tranexamic	1
Placebo	0

Average units packed red blood cells transfused among participants (NCT02684851)
Timeframe: perioperative

Intervention	participants (Number)
	Total invasive cancer	Cancer death
Aspirin + Vitamin E	716	152
Aspirin Only	722	132
Both Placebos	706	143
Vitamin E Only	721	156

Article	Year
What is the optimal management of thromboprophylaxis after liver transplantation regarding prevention of bleeding, hepatic artery, or portal vein thrombosis? A systematic review of the literature and expert panel recommendations. Clinical transplantation, 2022, Volume: 36, Issue:10 Topics: Anticoagulants; Aspirin; Hemorrhage; Hepatic Artery; Humans; Liver Diseases; Liver Transplantation;	2022
Comparison of non-criteria antiphospholipid syndrome with definite antiphospholipid syndrome: A systematic review. Frontiers in immunology, 2022, Volume: 13 Topics: Antiphospholipid Syndrome; Aspirin; Female; Humans; Pregnancy; Pregnancy Outcome; Thrombosis; Venous	2022
The role of aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis after total knee arthroplasty: a meta-analysis of randomized controlled trials. International journal of surgery (London, England), 2023, Nov-01, Volume: 109, Issue:11 Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Heparin; Heparin, Low-Molecular-Weight; Hu	2023
The efficacy and safety of aspirin in preventing venous thrombosis in major orthopedic surgery: An updated meta-analysis of randomized controlled trials. Medicine, 2023, Oct-20, Volume: 102, Issue:42 Topics: Anticoagulants; Aspirin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Orthopedic Procedures; P	2023
Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. The Cochrane database of systematic reviews, 2020, 05-06, Volume: 5 Topics: Adult; Anticoagulants; Arthroscopy; Aspirin; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecula	2020
Recent advances in understanding, diagnosing and treating venous thrombosis. F1000Research, 2020, Volume: 9 Topics: Anticoagulants; Aspirin; Humans; Venous Thromboembolism; Venous Thrombosis	2020
Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations. American journal of hematology, 2021, 03-01, Volume: 96, Issue:3 Topics: Abortion, Habitual; Abortion, Spontaneous; Anticoagulants; Aspirin; Combined Modality Therapy; Femal	2021
Comparison of Surgical Site Infection Risk Between Warfarin, LMWH, and Aspirin for Venous Thromboprophylaxis in TKA or THA: A Systematic Review and Meta-Analysis. JBJS reviews, 2020, 12-18, Volume: 8, Issue:12 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Heparin, L	2020
Low molecular weight heparin and aspirin for prevention of deep vein thrombosisafter orthopaedic surgery: a systematic review and meta-analysis. Journal of thrombosis and thrombolysis, 2021, Volume: 52, Issue:2 Topics: Anticoagulants; Aspirin; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Orthopedic Proc	2021
Upper Extremity Deep Venous Thrombosis Prophylaxis After Elective Upper Extremity Surgery. Orthopedics, 2018, Jan-01, Volume: 41, Issue:1 Topics: Aged; Aspirin; Cardiology; Comorbidity; Compression Bandages; Elective Surgical Procedures; Humans;	2018
Update on extended treatment for venous thromboembolism. Annals of medicine, 2018, Volume: 50, Issue:8 Topics: Administration, Oral; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Hemorrhage; Humans;	2018
Antithrombotic Agents. Circulation research, 2019, Volume: 124, Issue:3 Topics: Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clinical Trials a	2019
Rivaroxaban and the EINSTEIN clinical trial programme. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2019, Volume: 30, Issue:3 Topics: Adult; Aspirin; Child; Clinical Trials as Topic; Humans; Precision Medicine; Pulmonary Embolism; Riv	2019
Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis. PloS one, 2019, Volume: 14, Issue:4 Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Coagulation; Female; Hemorrhage; Heparin, Low-M	2019
Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months. Prescrire international, 2013, Volume: 22, Issue:138 Topics: Anticoagulants; Aspirin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Platelet Aggregation Inh	2013
The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities. European journal of internal medicine, 2014, Volume: 25, Issue:1 Topics: Age Factors; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management;	2014
Role of platelet inhibition in microvascular surgery. Journal of reconstructive microsurgery, 2014, Volume: 30, Issue:9 Topics: Angina, Unstable; Aspirin; Coronary Disease; Endothelium, Vascular; Free Tissue Flaps; Humans; Plate	2014
The year in cardiology 2014: peripheral circulation. European heart journal, 2015, Mar-07, Volume: 36, Issue:10 Topics: Anticoagulants; Aortic Aneurysm, Abdominal; Aspirin; Biomarkers; Carotid Artery Diseases; Endovascul	2015
[Aspirin and venous thromboses]. Der Internist, 2015, Volume: 56, Issue:1 Topics: Aspirin; Evidence-Based Medicine; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Trea	2015
What's New in Venous Thromboembolic Prophylaxis Following Total Knee and Total Hip Arthroplasty? An Update. Surgical technology international, 2015, Volume: 26 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Heparin; H	2015
Aspirin as Thromboprophylaxis in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis. The Journal of arthroplasty, 2016, Volume: 31, Issue:11 Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Fibrinolytic Agents; Hemor	2016
The 2016 American College of Chest Physicians treatment guidelines for venous thromboembolism: a review and critical appraisal. Internal and emergency medicine, 2016, Volume: 11, Issue:8 Topics: Anticoagulants; Aspirin; Guidelines as Topic; Humans; Thoracic Surgery; Venous Thromboembolism; Veno	2016
Rational thromboprophylaxis in medical inpatients: not quite there yet. The Medical journal of Australia, 2008, Nov-03, Volume: 189, Issue:9 Topics: Anticoagulants; Aspirin; Australia; Clinical Trials as Topic; Cost-Benefit Analysis; Evidence-Based	2008
Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thrombo-embolism in high-risk patients. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2009, Volume: 37, Issue:3 Topics: Aspirin; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Intermittent Pneumatic Compression D	2009
Thromboprophylaxis and obstetric management of the antiphospholipid syndrome. Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:4 Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Catastrophic Illness; Drug Therapy, Combi	2009
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1. Flight deep vein thrombosis prophylaxis in lower limb injury. Emergency medicine journal : EMJ, 2009, Volume: 26, Issue:4 Topics: Aerospace Medicine; Anticoagulants; Aspirin; Evidence-Based Medicine; Fractures, Bone; Heparin; Huma	2009
Management of antiphospholipid syndrome. Journal of autoimmunity, 2009, Volume: 33, Issue:2 Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Fibrinolyt	2009
Deep vein thrombosis: risk factors and prevention in surgical patients. West African journal of medicine, 2009, Volume: 28, Issue:2 Topics: Anticoagulants; Aspirin; Awareness; Clinical Competence; Cyclooxygenase Inhibitors; Dextrans; Dihydr	2009
DVT prophylaxis in total joint reconstruction. The Orthopedic clinics of North America, 2010, Volume: 41, Issue:2 Topics: Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement	2010
Economy class syndrome complicated by stroke: a rare condition due to paradoxical embolism--a case report and review of the literature. Journal of cardiovascular medicine (Hagerstown, Md.), 2011, Volume: 12, Issue:8 Topics: Aircraft; Anticoagulants; Aspirin; Clopidogrel; Echocardiography; Embolism, Paradoxical; Foramen Ova	2011
Perioperative management of the patient with rheumatoid arthritis. Clinics in podiatric medicine and surgery, 2010, Volume: 27, Issue:2 Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin; Cervical Vertebrae;	2010
Aspirin for lower limb arthroplasty thromboprophylaxis: review of international guidelines. Irish journal of medical science, 2011, Volume: 180, Issue:3 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Fondaparin	2011
All I want for coagulation. Scottish medical journal, 2011, Volume: 56, Issue:4 Topics: Aircraft; Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin; Holidays; Humans; Practice Guidelin	2011
Aspirin and Other COX-1 inhibitors. Handbook of experimental pharmacology, 2012, Issue:210 Topics: Animals; Aspirin; Atherosclerosis; Atrial Fibrillation; Cyclooxygenase 1; Cyclooxygenase Inhibitors;	2012
[What is the place of aspirin in venous thrombosis prophylaxis?]. Annales de cardiologie et d'angeiologie, 2002, Volume: 51, Issue:5 Topics: Aspirin; Evidence-Based Medicine; Fibrinolytic Agents; Humans; Practice Guidelines as Topic; Pulmona	2002
Thromboprophylaxis in patients undergoing total hip replacement. Hospital medicine (London, England : 1998), 2003, Volume: 64, Issue:5 Topics: Arthroplasty, Replacement, Hip; Aspirin; Bandages; Fibrinolytic Agents; Heparin, Low-Molecular-Weigh	2003
[Factor V Leiden mutation and pregnancy complications]. Medicina (Kaunas, Lithuania), 2003, Volume: 39, Issue:9 Topics: Abortion, Spontaneous; Activated Protein C Resistance; Adult; Anticoagulants; Aspirin; Factor V; Fem	2003
Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. The Cochrane database of systematic reviews, 2003, Issue:4 Topics: Anticoagulants; Aspirin; Female; Gynecologic Surgical Procedures; Heparin; Humans; Postoperative Com	2003
Duration of venous thromboembolism prophylaxis after surgery. Chest, 2003, Volume: 124, Issue:6 Suppl Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Drug Admin	2003
Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. Haematologica, 2003, Volume: 88, Issue:12 Topics: Adult; Aged; Aspirin; Blood Coagulation Factors; Blood Group Antigens; Ethnicity; Gonadal Steroid Ho	2003
Antiplatelet drugs in cardiovascular diseases. International journal of clinical practice, 2003, Volume: 57, Issue:10 Topics: Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Drug Resistance; Humans; Myocardial Infarctio	2003
The safety of antithrombotic therapy during pregnancy. Expert opinion on drug safety, 2004, Volume: 3, Issue:2 Topics: Anticoagulants; Aspirin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Practic	2004
The treatment and prevention of deep vein thrombosis in the preoperative management of patients who have neurologic diseases. Neurologic clinics, 2004, Volume: 22, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Brain Diseases; Chondroitin Sulfat	2004
Atrial fibrillation: should we target platelets or the coagulation pathway? Cardiac electrophysiology review, 2003, Volume: 7, Issue:4 Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Risk Assessment;	2003
Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin. Thrombosis and haemostasis, 2004, Volume: 92, Issue:1 Topics: Administration, Oral; Anticoagulants; Aspirin; Cost-Benefit Analysis; Factor Xa Inhibitors; Heparin;	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap	2004
Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arteriosclerosis, thrombosis, and vascular biology, 2004, Volume: 24, Issue:11 Topics: Aspirin; Clopidogrel; Drug Resistance; Humans; Ticlopidine; Treatment Failure; Treatment Outcome; Ve	2004
Guidelines and alternatives for neuraxial anesthesia and venous thromboembolism prophylaxis in major orthopedic surgery. The Journal of arthroplasty, 2004, Volume: 19, Issue:8 Topics: Anesthesia, Conduction; Anesthesia, General; Aspirin; Factor Xa Inhibitors; Heparin; Humans; Orthope	2004
Systemic lupus erythematosus with simultaneous onset of Kikuchi-Fujimoto's disease complicated with antiphospholipid antibody syndrome: a case report and review of the literature. Rheumatology international, 2005, Volume: 25, Issue:4 Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Anticoagulants; Antiphospholipid Syndrome; An	2005
Prevention of venous thromboembolism in medical and surgical patients. Cleveland Clinic journal of medicine, 2005, Volume: 72 Suppl 1 Topics: Anticoagulants; Aspirin; Bandages; Chemoprevention; Early Ambulation; Hospitalization; Humans; Risk	2005
Management problems of spontaneous ICH. Hospital medicine (London, England : 1998), 2005, Volume: 66, Issue:4 Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Hospitalization; Humans; Magnetic Reso	2005
Pharmacological prevention of venous thromboembolism in medical patients at risk. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2005, Volume: 5, Issue:6 Topics: Anticoagulants; Aspirin; Bandages; Clinical Trials as Topic; Heparin; Humans; Intermittent Pneumatic	2005
[The new antithrombotic agents]. Presse medicale (Paris, France : 1983), 2005, Oct-22, Volume: 34, Issue:18 Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Azetidines; Benzylami	2005
[Patient with antithrombotic medication. Which do bleedings or preoperative?]. Laryngo- rhino- otologie, 2006, Volume: 85, Issue:1 Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atherosc	2006
Multimodal venous thromboembolic disease prevention for patients undergoing primary or revision total joint arthroplasty: the role of aspirin. American journal of orthopedics (Belle Mead, N.J.), 2006, Volume: 35, Issue:1 Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Dose-Response Relationship	2006
Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thrombosis and haemostasis, 2006, Volume: 95, Issue:6 Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Embolism; Factor V; He	2006
Prevention of thrombosis with warfarin, aspirin, and mechanical methods. Clinical cornerstone, 2005, Volume: 7, Issue:4 Topics: Anticoagulants; Aspirin; Bandages; Combined Modality Therapy; Heparin, Low-Molecular-Weight; Intermi	2005
Aspirin in the prevention and treatment of venous thromboembolism. Journal of thrombosis and haemostasis : JTH, 2006, Volume: 4, Issue:7 Topics: Aspirin; Humans; Incidence; Secondary Prevention; Thromboembolism; Travel; Treatment Outcome; Venous	2006
When should prophylactic anticoagulation begin after a hip fracture? Cleveland Clinic journal of medicine, 2006, Volume: 73, Issue:9 Topics: Anticoagulants; Aspirin; Chemoprevention; Heparin; Hip Fractures; Humans; Risk Assessment; Risk Fact	2006
Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation. Nature clinical practice. Cardiovascular medicine, 2006, Volume: 3, Issue:12 Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Admi	2006
Travel-related thrombosis: is this a problem? The Israel Medical Association journal : IMAJ, 2006, Volume: 8, Issue:12 Topics: Aerospace Medicine; Aircraft; Anticoagulants; Aspirin; Chemoprevention; Heparin; Humans; Posture; Pr	2006
[Application of anticoagulating medicine after surgery of cavity of pelvis and abdomen]. Zhonghua wai ke za zhi [Chinese journal of surgery], 2006, Oct-01, Volume: 44, Issue:19 Topics: Abdomen; Anticoagulants; Aspirin; Heparin; Humans; Pelvis; Postoperative Complications; Venous Throm	2006
Risk of thrombosis with lenalidomide and its prevention with aspirin. Chest, 2007, Volume: 131, Issue:1 Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Humans; Lenalidomide; Multiple Myeloma; Thalidomide;	2007
[Thromboembolic diseases in pregnancy]. Zeitschrift fur Geburtshilfe und Neonatologie, 2007, Volume: 211, Issue:1 Topics: Algorithms; Anticoagulants; Aspirin; Contraindications; Coumarins; Female; Heparin; Heparin, Low-Mol	2007
Major arterial involvement and review of Behcet's disease. Annals of vascular surgery, 2007, Volume: 21, Issue:2 Topics: Adrenal Cortex Hormones; Adult; Aneurysm, False; Anticoagulants; Aortic Aneurysm, Abdominal; Arteria	2007
WITHDRAWN: Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. The Cochrane database of systematic reviews, 2007, Jul-18, Issue:4 Topics: Anticoagulants; Aspirin; Female; Gynecologic Surgical Procedures; Heparin; Humans; Postoperative Com	2007
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of the National Cancer Institute, 2007, Aug-15, Volume: 99, Issue:16 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com	2007
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of the National Cancer Institute, 2007, Aug-15, Volume: 99, Issue:16 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com	2007
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of the National Cancer Institute, 2007, Aug-15, Volume: 99, Issue:16 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com	2007
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of the National Cancer Institute, 2007, Aug-15, Volume: 99, Issue:16 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com	2007
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of the National Cancer Institute, 2007, Aug-15, Volume: 99, Issue:16 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com	2007
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of the National Cancer Institute, 2007, Aug-15, Volume: 99, Issue:16 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com	2007
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of the National Cancer Institute, 2007, Aug-15, Volume: 99, Issue:16 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com	2007
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of the National Cancer Institute, 2007, Aug-15, Volume: 99, Issue:16 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com	2007
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of the National Cancer Institute, 2007, Aug-15, Volume: 99, Issue:16 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com	2007
Aspirin prophylaxis for thromboembolic disease after total joint arthroplasty. American journal of orthopedics (Belle Mead, N.J.), 2007, Volume: 36, Issue:9 Suppl Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement; Aspirin; Humans; Postoperative C	2007
[Brief report: stroke in multiple myeloma patient treated with thalidomide]. Rinsho shinkeigaku = Clinical neurology, 2007, Volume: 47, Issue:9 Topics: Aged; Anticoagulants; Aspirin; Embolism, Paradoxical; Foramen Ovale, Patent; Humans; Male; Multiple	2007
[Vascular complications of essential thrombocythemia]. Bulletin de l'Academie nationale de medecine, 2007, Volume: 191, Issue:3 Topics: Age Factors; Aspirin; Case-Control Studies; Controlled Clinical Trials as Topic; Humans; Middle Aged	2007
Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism. Blood reviews, 2008, Volume: 22, Issue:2 Topics: Aspirin; Clinical Trials as Topic; Humans; Platelet Aggregation Inhibitors; Venous Thromboembolism;	2008
Platelets, aspirin, and cardiovascular disease. Postgraduate medical journal, 1998, Volume: 74, Issue:876 Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Platelet Adhesivenes	1998
Travelling with heart disease. The Practitioner, 1998, Volume: 242, Issue:1583 Topics: Alcohol Drinking; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Dehydration; Diet; Heart Diseas	1998
[Phospholipid antigens, thrombosis and repeated fetal death]. Duodecim; laaketieteellinen aikakauskirja, 1996, Volume: 112, Issue:3 Topics: Abortion, Habitual; Adult; Antigens; Aspirin; Biomarkers; Enzyme-Linked Immunosorbent Assay; Female;	1996
Vascular drugs in the new millennium. Journal of the American College of Surgeons, 2000, Volume: 191, Issue:1 Topics: Abciximab; Animals; Anistreplase; Antibodies, Monoclonal; Anticoagulants; Aspirin; Chondroitin Sulfa	2000
A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. The Journal of bone and joint surgery. American volume, 2000, Volume: 82-A, Issue:7 Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Chemoprevention; Confidence Intervals	2000
Use of antithrombotic agents during pregnancy. Chest, 2001, Volume: 119, Issue:1 Suppl Topics: Aspirin; Female; Fetus; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregn	2001
Antithrombotic agents in coronary artery disease. Chest, 2001, Volume: 119, Issue:1 Suppl Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Embolism; Fibrinolytic Agents; Humans; Platelet	2001
A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. The Journal of arthroplasty, 2001, Volume: 16, Issue:3 Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Male;	2001
A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. The Journal of arthroplasty, 2001, Volume: 16, Issue:3 Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Male;	2001
A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. The Journal of arthroplasty, 2001, Volume: 16, Issue:3 Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Male;	2001
A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. The Journal of arthroplasty, 2001, Volume: 16, Issue:3 Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Male;	2001
A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. The Journal of arthroplasty, 2001, Volume: 16, Issue:3 Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Male;	2001
A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. The Journal of arthroplasty, 2001, Volume: 16, Issue:3 Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Male;	2001
A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. The Journal of arthroplasty, 2001, Volume: 16, Issue:3 Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Male;	2001
A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. The Journal of arthroplasty, 2001, Volume: 16, Issue:3 Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Male;	2001
A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. The Journal of arthroplasty, 2001, Volume: 16, Issue:3 Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Male;	2001
[Acetylsalicylic acid and bioptic methods in pneumology]. Pneumologie (Stuttgart, Germany), 2001, Volume: 55, Issue:6 Topics: Aspirin; Biopsy; Bronchoscopy; Cardiovascular Diseases; Fiber Optic Technology; Humans; Lung; Venous	2001
COX-2 inhibition and thrombotic tendency: a need for surveillance. The Medical journal of Australia, 2001, Aug-20, Volume: 175, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase I	2001
Screening for subclinical deep-vein thrombosis. QJM : monthly journal of the Association of Physicians, 2001, Volume: 94, Issue:10 Topics: Anticoagulants; Aspirin; Fibrin Fibrinogen Degradation Products; Fibrinogen; Fibrinolytic Agents; He	2001
An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I. Seminars in urologic oncology, 2001, Volume: 19, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2; Cycloox	2001
[Advances and perspectives in the prevention of venous thromboembolic disease]. Archives des maladies du coeur et des vaisseaux, 2001, Volume: 94, Issue:11 Suppl Topics: Anesthesia, Conduction; Anticoagulants; Aspirin; Heparin, Low-Molecular-Weight; Humans; Myocardial I	2001
The use of antithrombotic drugs in older people. Minerva medica, 2002, Volume: 93, Issue:1 Topics: Aged; Aspirin; Clopidogrel; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Myo	2002
Antithrombotic agents: implications in dentistry. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2002, Volume: 93, Issue:5 Topics: Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Dental Care; Drug Interactions; Embol	2002

Intervention	Participants (Number)
	Major cardiovascular event	Stroke	Myocardial infarction	Cardiovascular death
Aspirin + Vitamin E	232	108	102	54
Aspirin Only	245	113	96	66
Both Placebos	272	133	99	74
Vitamin E Only	250	133	94	52

aspirin and Venous Thrombosis

Research Excerpts

Research

Studies (316)

Authors

Clinical Trials (35)

Trial Overview

Trial Outcomes

Number of Participants Experiencing a Venous Thromboembolism

Number of Participants With at Least One Adverse Event

Event Rate of All-Cause Mortality (ACM) or Re-Hospitalization for Worsening Heart Failure

Event Rate of All-Cause Mortality, Myocardial Infarction (MI), or Stroke

Event Rate of Bleeding Events That Requiring Hospitalization

Event Rate of Cardio Vascular Death

Event Rate of Cardio Vascular Death or Re-Hospitalization for Worsening of Heart Failure (RHHF)

Event Rate of International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding Event

Event Rate of Re-Hospitalization for Cardio Vascular Events (RHCV)

Event Rate of Re-Hospitalization for Worsening of Heart Failure

Event Rate of Either Fatal Bleeding or Bleeding Into a Critical Space With Potential for Permanent Disability

Number of Participants With Deep Venous Thromboembolism

Number of Participants With Pulmonary Embolism Events

Number of Participants With Treatment-related Bleeding Events as Assessed by the Need for Blood Transfusions and Procedures for Bleeding Complications After Initiation of the Study Medication.

Number of Participants With Cardiovascular Death or Thromboembolic Event

Number of Participants With Composite Bleeding Endpoint of BARC (Bleeding Academic Research Consortium) 2, 3, or 5 Bleeds

Number of Participants With Death or First Thromboembolic Event (DTE)

Number of Participants With Death or First Thromboembolic Event (DTE)

Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeds

Number of Participants With Net-clinical Benefit

Number of Participants With Primary Bleeding Event (PBE)

Number of Participants With TIMI (Thrombolysis In Myocardial Infarction) Major / Minor Bleeds

Percentage of Patients Prescribed Appropriate VTE Prophylaxis

Increased Bleeding Attributed to Fondaparinux

Normal Trough and Peak Fondaparinux Concentration

Presence of Deep Vein Thrombosis (DVT) or Pulmonary Embolus (PE)

Allogenic Blood Transfusion Rates

Estimate Blood Loss

Number of Participants With a Thromboembolic Event

Units of Packed Red Blood Cells Transfused

Number of Participants With Cancer, Excluding Nonmelanoma Skin Cancer

Number of Participants With Major Cardiovascular Events (a Combined Endpoint of Nonfatal Myocardial Infarction, Nonfatal Stroke, and Total Cardiovascular Death)

Reviews

Trials

Other Studies